<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">NPJ Genom Med</journal-id>
<journal-id journal-id-type="iso-abbrev">NPJ Genom Med</journal-id>
<journal-title-group>
<journal-title>NPJ Genomic Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2056-7944</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31452935</article-id>
<article-id pub-id-type="pmc">6707204</article-id>
<article-id pub-id-type="publisher-id">93</article-id>
<article-id pub-id-type="doi">10.1038/s41525-019-0093-8</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Feliciano</surname>
<given-names>Pamela</given-names>
</name>
<address>
<email>pfeliciano@simonsfoundation.org</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2350-081X</contrib-id>
<name>
<surname>Zhou</surname>
<given-names>Xueya</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5328-4631</contrib-id>
<name>
<surname>Astrovskaya</surname>
<given-names>Irina</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8246-6477</contrib-id>
<name>
<surname>Turner</surname>
<given-names>Tychele N.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Tianyun</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brueggeman</surname>
<given-names>Leo</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barnard</surname>
<given-names>Rebecca</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4227-1952</contrib-id>
<name>
<surname>Hsieh</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snyder</surname>
<given-names>LeeAnne Green</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muzny</surname>
<given-names>Donna M.</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sabo</surname>
<given-names>Aniko</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<collab>The SPARK Consortium<contrib-group><contrib contrib-type="author"><name><surname>Abbeduto</surname><given-names>Leonard</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Acampado</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ace</surname><given-names>Andrea J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Albright</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Alessandri</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Amaral</surname><given-names>David G.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Amatya</surname><given-names>Alpha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Annett</surname><given-names>Robert D.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Arriaga</surname><given-names>Ivette</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Bahl</surname><given-names>Ethan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Balasubramanian</surname><given-names>Adithya</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Bardett</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Bashar</surname><given-names>Asif</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beaudet</surname><given-names>Arthur</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Beeson</surname><given-names>Landon</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Bernier</surname><given-names>Raphael A.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Berry-Kravis</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff19">19</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Booker</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Brewster</surname><given-names>Stephanie J.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Brooks</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Butler</surname><given-names>Martin E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Butter</surname><given-names>Eric M.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Callahan</surname><given-names>Kristen</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Camba</surname><given-names>Alexies</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Carpenter</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Carriero</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cartner</surname><given-names>Lindsey A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chatha</surname><given-names>Ahmad S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chin</surname><given-names>Wubin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Renee D.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Cheryl</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Courchesne</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Cubells</surname><given-names>Joseph F.</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Currin</surname><given-names>Mary Hannah</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Daniels</surname><given-names>Amy M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>DeMarco</surname><given-names>Lindsey</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Dennis</surname><given-names>Megan Y.</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name><surname>Dichter</surname><given-names>Gabriel S.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Dinh</surname><given-names>Huyen</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Doan</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Doddapaneni</surname><given-names>HarshaVardhan</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Eldred</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Eng</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Erickson</surname><given-names>Craig A.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Esler</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name><surname>Fatemi</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>J. Fischer</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Fisk</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fombonne</surname><given-names>Eric J.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Emily A.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Francis</surname><given-names>Sunday</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Friedman</surname><given-names>Sandra L.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Ganesan</surname><given-names>Swami</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Garrett</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name><surname>Gazestani</surname><given-names>Vahid</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Geisheker</surname><given-names>Madeleine R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gerdts</surname><given-names>Jennifer A.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Geschwind</surname><given-names>Daniel H.</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Goin-Kochel</surname><given-names>Robin P.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Griswold</surname><given-names>Anthony J.</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name><surname>Grosvenor</surname><given-names>Luke P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gruber</surname><given-names>Angela J.</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Gulsrud</surname><given-names>Amanda C.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Gunderson</surname><given-names>Jaclyn</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Gutierrez</surname><given-names>Anibal</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Hale</surname><given-names>Melissa N.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Haley</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Jacob B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hamer</surname><given-names>Kira E.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hanna</surname><given-names>Nathan</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Harkins</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Hauf</surname><given-names>Brenda</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Hayes</surname><given-names>Caitlin</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Hepburn</surname><given-names>Susan L.</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author"><name><surname>Herbert</surname><given-names>Lynette M.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Heyman</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Brittani A.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Horner</surname><given-names>Susannah</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Jianhong</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Huang-Storms</surname><given-names>Lark Y.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Hutter</surname><given-names>Hanna</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Istephanous</surname><given-names>Dalia</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Jacob</surname><given-names>Suma</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Jensen</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Jordy</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Juarez</surname><given-names>A. Pablo</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name><surname>Kanne</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff44">44</xref><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Hannah E.</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Kent</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kitaygorodsky</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Koomar</surname><given-names>Tanner</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Korchina</surname><given-names>Viktoriya</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Krentz</surname><given-names>Anthony D.</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>Hoa Lam</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Lamarche</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Landa</surname><given-names>Rebecca J.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Lash</surname><given-names>Alex E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Law</surname><given-names>J. Kiely</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Lawson</surname><given-names>Noah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Layman</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lechniak</surname><given-names>Holly</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Soo J.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Coury</surname><given-names>Daniel Lee</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Christa Lese</given-names></name><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Deana</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hai</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Lillie</surname><given-names>Natasha</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiuping</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Lord</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author"><name><surname>Mallardi</surname><given-names>Malcolm D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Manning</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Manoharan</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marini</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marzano</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Mason</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Matthews</surname><given-names>Emily T.</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>McCracken</surname><given-names>James T.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>McKenzie</surname><given-names>Alexander P.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Momin</surname><given-names>Zeineen</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Morrier</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Murali</surname><given-names>Shwetha</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Myers</surname><given-names>Vincent J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Neely</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Nessner</surname><given-names>Caitlin</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Nicholson</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name><surname>O’Brien</surname><given-names>Kaela</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>O’Connor</surname><given-names>Eirene</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ochoa-Lubinoff</surname><given-names>Cesar</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Orobio</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Ousley</surname><given-names>Opal Y.</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Pacheco</surname><given-names>Lillian D.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Pandey</surname><given-names>Juhi</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Paolicelli</surname><given-names>Anna Marie</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name><surname>Pawlowski</surname><given-names>Katherine G.</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>Pierce</surname><given-names>Karen L.</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Piven</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Plate</surname><given-names>Samantha</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Popp</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>Pramparo</surname><given-names>Tiziano</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Prock</surname><given-names>Lisa M.</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Hongjian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Shanping</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name><surname>Rachubinski</surname><given-names>Angela L.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Rajbhandari</surname><given-names>Kshitij</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Rana</surname><given-names>Rishiraj</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Remington</surname><given-names>Rick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>Catherine E.</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Rigby</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Robertson</surname><given-names>Beverly E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Roeder</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Rosenberg</surname><given-names>Cordelia R.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Russo-Ponsaran</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name><surname>Ruzzo</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name><surname>Sahin</surname><given-names>Mustafa</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name><surname>Salomatov</surname><given-names>Andrei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sandhu</surname><given-names>Sophia</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Santangelo</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name><surname>Sarver</surname><given-names>Dustin E.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Scherr</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Schultz</surname><given-names>Robert T.</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Schweers</surname><given-names>Kathryn A.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Swapnil</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shaikh</surname><given-names>Tamim</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Shocklee</surname><given-names>Amanda D.</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name><surname>Simon</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>Simon</surname><given-names>Andrea R.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Vini</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Skinner</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Kaitlin</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Christopher J.</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name><surname>Soorya</surname><given-names>Latha V.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Soucy</surname><given-names>Aubrie</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Stephens</surname><given-names>Alexandra N.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stock</surname><given-names>Colleen M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sutcliffe</surname><given-names>James S.</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name><surname>Swanson</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Tafolla</surname><given-names>Maira</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Taylor</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Carrie</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Samantha</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Tjernagel</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Van Metre</surname><given-names>Bonnie</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Veenstra-Vanderweele</surname><given-names>Jeremy</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><contrib contrib-type="author"><name><surname>Vernoia</surname><given-names>Brianna M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wallace</surname><given-names>Jermel</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Walston</surname><given-names>Corrie H.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jiayao</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Warren</surname><given-names>Zachary</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name><surname>Wasserburg</surname><given-names>Lucy</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Loran Casey</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Sabrina</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Wodka</surname><given-names>Ericka L.</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Wha S.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Yinger</surname><given-names>Meredith</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Zang</surname><given-names>Lan</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Zaydens</surname><given-names>Hana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Haicang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Haoquan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib></contrib-group></collab>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gibbs</surname>
<given-names>Richard A.</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8246-4014</contrib-id>
<name>
<surname>Eichler</surname>
<given-names>Evan E.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4141-0095</contrib-id>
<name>
<surname>O’Roak</surname>
<given-names>Brian J.</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9713-0992</contrib-id>
<name>
<surname>Michaelson</surname>
<given-names>Jacob J.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Volfovsky</surname>
<given-names>Natalia</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1299-5979</contrib-id>
<name>
<surname>Shen</surname>
<given-names>Yufeng</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chung</surname>
<given-names>Wendy K.</given-names>
</name>
<address>
<email>wkc15@cumc.columbia.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430264.7</institution-id><institution>Simons Foundation, </institution></institution-wrap>New York, NY 10010 USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution>Department of Systems Biology, </institution><institution>Columbia University, </institution></institution-wrap>New York, NY 10032 USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Department of Genome Sciences, </institution><institution>University of Washington School of Medicine, </institution></institution-wrap>Seattle, WA 98195 USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8294</institution-id><institution-id institution-id-type="GRID">grid.214572.7</institution-id><institution>Department of Psychiatry, </institution><institution>University of Iowa Carver College of Medicine, </institution></institution-wrap>Iowa City, IA 52242 USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution>Department of Molecular and Medical Genetics, </institution><institution>Oregon Health &amp; Science University, </institution></institution-wrap>Portland, OR 97239 USA </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution>Human Genome Sequencing Center, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX 77030 USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Howard Hughes Medical Institute, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA 98195 USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2285 2675</institution-id><institution-id institution-id-type="GRID">grid.239585.0</institution-id><institution>Department of Pediatrics, </institution><institution>Columbia University Medical Center, </institution></institution-wrap>New York, NY 10032 USA </aff>
<aff id="Aff9"><label>9</label>MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento, CA 95817 USA </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0392 3476</institution-id><institution-id institution-id-type="GRID">grid.240344.5</institution-id><institution>Division of Pediatric Psychology and Neuropsychology, </institution><institution>Nationwide Children’s Hospital, </institution></institution-wrap>Columbus, Ohio 43205 USA </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8606</institution-id><institution-id institution-id-type="GRID">grid.26790.3a</institution-id><institution>Department of Psychology, </institution><institution>University of Miami, </institution></institution-wrap>Coral Gables, FL 33146 USA </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0407</institution-id><institution-id institution-id-type="GRID">grid.410721.1</institution-id><institution>Department of Pediatrics, </institution><institution>University of Mississippi Medical Center, </institution></institution-wrap>Jackson, MS 39216 USA </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution>Department of Psychiatry and Biobehavioral Sciences, </institution><institution>University of California, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution>Department of Molecular and Human Genetics, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX 77030 USA </aff>
<aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9916</institution-id><institution-id institution-id-type="GRID">grid.412807.8</institution-id><institution>Vanderbilt Kennedy Center, </institution><institution>Vanderbilt University Medical Center, </institution></institution-wrap>Nashville, TN 37232 USA </aff>
<aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Department of Psychiatry and Behavioral Sciences, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff>
<aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Department of Psychiatry and Behavioral Sciences, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA 98195 USA </aff>
<aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Department of Neurological Sciences, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff>
<aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Department of Pediatrics, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff>
<aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Department of Biochemistry, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff>
<aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9025 8099</institution-id><institution-id institution-id-type="GRID">grid.239573.9</institution-id><institution>Department of Psychiatry and Behavioral Neuroscience, </institution><institution>Cincinnati Children’s Hospital Medical Center - Research Foundation, </institution></institution-wrap>Cincinnati, OH 45229 USA </aff>
<aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Translational Neuroscience Center, </institution><institution>Boston Children’s Hospital, </institution></institution-wrap>Boston, MA 02115 USA </aff>
<aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution>Department of Psychiatry, </institution><institution>University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, NC 27599 USA </aff>
<aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0427 667X</institution-id><institution-id institution-id-type="GRID">grid.240023.7</institution-id><institution>Hugo W. Moser Research Institute at Kennedy Krieger, </institution></institution-wrap>Baltimore, MD 21211 USA </aff>
<aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution>Department of Neurosciences, </institution><institution>University of California, San Diego, School of Medicine, </institution></institution-wrap>La Jolla, CA 92037 USA </aff>
<aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Department of Psychiatry and Behavioral Sciences, Emory Autism Center, </institution><institution>Emory University, </institution></institution-wrap>Atlanta, GA 30033 USA </aff>
<aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0680 8770</institution-id><institution-id institution-id-type="GRID">grid.239552.a</institution-id><institution>Center for Autism Research, </institution><institution>Children’s Hospital of Philadelphia, </institution></institution-wrap>Philadelphia, PA 19146 USA </aff>
<aff id="Aff28"><label>28</label>Genome Center, MIND Institute, Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA 95616 USA </aff>
<aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Department of Medicine, </institution><institution>Boston Childrens Hospital, </institution></institution-wrap>Boston, MA 02115 USA </aff>
<aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ISNI">0000000419368657</institution-id><institution-id institution-id-type="GRID">grid.17635.36</institution-id><institution>Department of Pediatrics, </institution><institution>University of Minnesota, </institution></institution-wrap>Minneapolis, MN 55414 USA </aff>
<aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0427 667X</institution-id><institution-id institution-id-type="GRID">grid.240023.7</institution-id><institution>Center for Autism and Related Disorders, </institution><institution>Kennedy Krieger Institute, </institution></institution-wrap>Baltimore, MD 21211 USA </aff>
<aff id="Aff32"><label>32</label>PreventionGenetics, Marshfield, WI 54449 USA </aff>
<aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution>Departments of Pediatrics &amp; Psychiatry, </institution><institution>Oregon Health &amp; Science University, </institution></institution-wrap>Portland, OR 97239 USA </aff>
<aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="ISNI">0000000419368657</institution-id><institution-id institution-id-type="GRID">grid.17635.36</institution-id><institution>Department of Psychiatry, </institution><institution>University of Minnesota, </institution></institution-wrap>Minneapolis, MN 55455 USA </aff>
<aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution>Department of Pediatrics, </institution><institution>University of Colorado School of Medicine, </institution></institution-wrap>Aurora, CO 80045 USA </aff>
<aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0407</institution-id><institution-id institution-id-type="GRID">grid.410721.1</institution-id><institution>Department of Pharmacology and Toxicology, </institution><institution>University of Mississippi Medical Center, </institution></institution-wrap>Jackson, MS 39216 USA </aff>
<aff id="Aff37"><label>37</label>Department of Pediatrics, University of California, San Diego, La Jolla, CA 92161 USA </aff>
<aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution>Department of Neurology, </institution><institution>University of California, </institution></institution-wrap>Los Angeles, CA 90095 USA </aff>
<aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution>Department of Pediatrics, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>Houston, TX 77030 USA </aff>
<aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8606</institution-id><institution-id institution-id-type="GRID">grid.26790.3a</institution-id><institution>John P. Hussman Institute for Human Genomics, </institution><institution>University of Miami Miller School of Medicine, </institution></institution-wrap>Miami, FL 33136 USA </aff>
<aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8083</institution-id><institution-id institution-id-type="GRID">grid.47894.36</institution-id><institution>Human Development &amp; Family Studies, </institution><institution>Colorado State University, </institution></institution-wrap>Fort Collins, CO 80524 USA </aff>
<aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936877X</institution-id><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution>Department of Psychiatry, </institution><institution>Weill Cornell Medicine, White Plains, </institution></institution-wrap>New York, 10605 USA </aff>
<aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9916</institution-id><institution-id institution-id-type="GRID">grid.412807.8</institution-id><institution>Department of Pediatrics, </institution><institution>Vanderbilt University Medical Center, </institution></institution-wrap>Nashville, TN 37232 USA </aff>
<aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2162 3504</institution-id><institution-id institution-id-type="GRID">grid.134936.a</institution-id><institution>Department of Health Psychology, </institution><institution>University of Missouri, </institution></institution-wrap>Columbia, MO 65211 USA </aff>
<aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2162 3504</institution-id><institution-id institution-id-type="GRID">grid.134936.a</institution-id><institution>Thompson Center for Autism and Neurodevelopmental Disorders, </institution><institution>University of Missouri, </institution></institution-wrap>Columbia, MO 65211 USA </aff>
<aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="GRID">grid.476963.9</institution-id><institution>Geisinger Autism &amp; Developmental Medicine Institute, </institution></institution-wrap>Lewisburg, PA 17837 USA </aff>
<aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9632 6718</institution-id><institution-id institution-id-type="GRID">grid.19006.3e</institution-id><institution>David Geffen School of Medicine, </institution><institution>Semel Institute for Neuroscience and Human Behavior, University of California, </institution></institution-wrap>Los Angeles, CA 90024 USA </aff>
<aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="GRID">grid.430554.3</institution-id><institution>Research, Southwest Autism Research and Resource Center, </institution></institution-wrap>Phoenix, AZ 85006 USA </aff>
<aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Department of Pediatrics, </institution><institution>Boston Children’s Hospital, </institution></institution-wrap>Boston, MA 02115 USA </aff>
<aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Department of Behavioral Sciences, </institution><institution>Rush University Medical Center, </institution></institution-wrap>Chicago, IL 60612 USA </aff>
<aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Department of Neurology, </institution><institution>Boston Children’s Hospital, </institution></institution-wrap>Boston, MA 02115 USA </aff>
<aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0433 3945</institution-id><institution-id institution-id-type="GRID">grid.416311.0</institution-id><institution>Maine Medical Center Research Institute, </institution></institution-wrap>Portland, ME 04101 USA </aff>
<aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8571 0933</institution-id><institution-id institution-id-type="GRID">grid.418307.9</institution-id><institution>Greenwood Genetic Center, </institution></institution-wrap>Greenwood, SC 29646 USA </aff>
<aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2264 7217</institution-id><institution-id institution-id-type="GRID">grid.152326.1</institution-id><institution>Department of Molecular Physiology &amp; Biophysics, </institution><institution>Vanderbilt University, </institution></institution-wrap>Nashville, TN 37232 USA </aff>
<aff id="Aff55"><label>55</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2285 2675</institution-id><institution-id institution-id-type="GRID">grid.239585.0</institution-id><institution>Department of Psychiatry, </institution><institution>Columbia University Medical Center, </institution></institution-wrap>New York, NY 10032 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>23</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>4</volume>
<elocation-id>19</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Autism spectrum disorder (ASD) is a genetically heterogeneous condition, caused by a combination of rare de novo and inherited variants as well as common variants in at least several hundred genes. However, significantly larger sample sizes are needed to identify the complete set of genetic risk factors. We conducted a pilot study for SPARK (SPARKForAutism.org) of 457 families with ASD, all consented online. Whole exome sequencing (WES) and genotyping data were generated for each family using DNA from saliva. We identified variants in genes and loci that are clinically recognized causes or significant contributors to ASD in 10.4% of families without previous genetic findings. In addition, we identified variants that are possibly associated with ASD in an additional 3.4% of families. A meta-analysis using the TADA framework at a false discovery rate (FDR) of 0.1 provides statistical support for 26 ASD risk genes. While most of these genes are already known ASD risk genes, <italic>BRSK2</italic> has the strongest statistical support and reaches genome-wide significance as a risk gene for ASD (<italic>p</italic>-value = 2.3e−06). Future studies leveraging the thousands of individuals with ASD who have enrolled in SPARK are likely to further clarify the genetic risk factors associated with ASD as well as allow accelerate ASD research that incorporates genetic etiology.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject">
<title>Subject terms</title>
<kwd>Behavioural genetics</kwd>
<kwd>Autism spectrum disorders</kwd>
<kwd>Medical genomics</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000893</institution-id>
<institution>Simons Foundation</institution>
</institution-wrap>
</funding-source>
<award-id>SFARI #608045</award-id>
<award-id>SFARI #608045</award-id>
<award-id>SFARI #608045</award-id>
<principal-award-recipient>
<name>
<surname>Feliciano</surname>
<given-names>Pamela</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Tianyun</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>Evan E.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000025</institution-id>
<institution>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</institution>
</institution-wrap>
</funding-source>
<award-id>R01MH101221</award-id>
<award-id>1K99MH117165</award-id>
<award-id>R01MH101221</award-id>
<award-id>R01MH101221</award-id>
<principal-award-recipient>
<name>
<surname>Feliciano</surname>
<given-names>Pamela</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Tianyun</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>Evan E.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/100005440</institution-id>
<institution>U.S. Department of Health &amp; Human Services | NIH | Center for Scientific Review (NIH Center for Scientific Review)</institution>
</institution-wrap>
</funding-source>
<award-id>MH105527</award-id>
<award-id>DC014489</award-id>
<principal-award-recipient>
<name>
<surname>Feliciano</surname>
<given-names>Pamela</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000011</institution-id>
<institution>Howard Hughes Medical Institute (HHMI)</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
<institution>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</institution>
</institution-wrap>
</funding-source>
<award-id>1K99MH117165</award-id>
<award-id>MH105527</award-id>
<award-id>DC014489</award-id>
<principal-award-recipient>
<name>
<surname>Turner</surname>
<given-names>Tychele N.</given-names>
</name>
<name>
<surname>Brueggeman</surname>
<given-names>Leo</given-names>
</name>
<name>
<surname>Michaelson</surname>
<given-names>Jacob J.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par2">Autism spectrum disorder (ASD) is an extremely variable condition characterized by deficits in social interactions and restrictive, repetitive behaviors. Currently, there are no FDA approved medications that address these core symptoms, despite the life-long morbidity and increased mortality in adults with ASD.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup></p>
<p id="Par3">Despite the significant clinical heterogeneity of this condition, many studies have shown that ASD is highly heritable, with genetic risk factors thought to explain the majority of the risk for ASD.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> Over the past decade, genomic studies focused on de novo, likely gene disrupting (dnLGD) variants (stopgain, frameshift, and essential splice site) have identified ~100 high-confidence ASD risk genes or loci.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup> Previous studies have identified molecular diagnoses in 6–37% of individuals with ASD, with higher yields in individuals with additional co-morbidities that include intellectual disabilities, seizures, and other medical features.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup></p>
<p id="Par4">Here we describe the results of a pilot study that genetically characterized 457 families with one or more members affected with ASD enrolled online in SPARK.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> SPARK’s mission is to create the largest recontactable research cohort of at least 50,000 families affected with ASD in the United States for longitudinal phenotypic and genomic characterization who are available to participate in research studies. Using exome sequencing and genome-wide single nucleotide polymorphism (SNP) genotyping arrays, we identified variants that are the likely primary genetic cause of ASD in 14% of families. We also demonstrated that the genetic architecture in this self-reported cohort is similar to published, clinically confirmed ASD cohorts.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup> Combining the SPARK data with prior studies, our analyses provide strong evidence that <italic>BRSK2</italic> is a high-confidence ASD risk gene (FDR <italic>q</italic>-value = 0.0015) and provide evidence that strengthens the association of additional genes (<italic>FEZF2, ITSN1, PAX5, DMWD</italic>, and <italic>CPZ</italic>) in ASD.</p>
</sec>
<sec id="Sec2" sec-type="results">
<title>Results</title>
<sec id="Sec3">
<title>Variant discovery</title>
<p id="Par5">We report the exome sequencing and genotyping results of 1379 individuals in 457 families with at least one offspring affected with ASD, including 418 simplex and 39 multiplex families (Supplementary Fig. <xref ref-type="media" rid="MOESM1">1</xref>). Over 80% of participants are predicted to have European ancestry based on principal component analysis of common SNP genotypes (Supplementary Fig. <xref ref-type="media" rid="MOESM1">2</xref>). The male to female ratio is 4.4:1 among 418 offspring cases in simplex families, and 2.9:1 among 47 offspring cases in multiplex families. Of the 465 offspring affected with ASD, 25.6% also reported intellectual disability (Table <xref ref-type="table" rid="Tab1">1</xref>). We identified 647 rare (allele frequency (AF) &lt;0.001 in ExAC v0.3) de novo single nucleotide variants (SNVs) and indels (Supplementary Data <xref ref-type="media" rid="MOESM3">1</xref>) in coding regions and splice sites (1.4/offspring), including 85 likely gene disrupting (LGD) variants and 390 missense variants. Similar to the de novo variants identified from 4773 clinically ascertained ASD trios from previous studies,<sup><xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup> the frequency of dnLGD variants in the 465 affected offspring in SPARK (0.18/offspring) is 1.76-fold higher than the baseline expectation calculated by a previously published mutation rate model<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> (<italic>p</italic>-value = 1.2 × 10<sup>−6</sup> by one-sided exact Poisson test) (“Methods”; Supplementary Data <xref ref-type="media" rid="MOESM4">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Phenotypic description of the 457 families with at least one offspring affected with ASD in the SPARK pilot study</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9">All offspring with ASD</th></tr><tr><th>Role</th><th><italic>n</italic> = 465</th><th>Average age (years) of ASD diagnosis</th><th>Average age (years) at enrollment (SD)</th><th>Range of age (years) at enrollment</th><th>Intellectual disability (%)</th><th>Nonverbal (%)</th><th>Epilepsy (%)</th><th>ADHD (%)</th></tr></thead><tbody><tr><td>Affected male offspring</td><td>376</td><td>4.8</td><td>12.9 (8.4)</td><td>1.5–44.6</td><td>22% (78/356)</td><td>13% (46/356)</td><td>7% (25/356)</td><td>30% (106/356)</td></tr><tr><td>Affected female offspring</td><td>89</td><td>5.6</td><td>12.8 (7.3)</td><td>1.9–29.8</td><td>33% (28/84)</td><td>10% (8/84)</td><td>13% (11/84)</td><td>23% (19/84)</td></tr></tbody></table><table-wrap-foot><p>1379 individuals in 39 multiplex and 418 simplex families were genomically characterized, including 472 individuals (465 offspring and 7 parents) affected with ASD. All phenotypic variables are not available for all participants</p></table-wrap-foot></table-wrap></p>
<p id="Par6">To identify de novo missense variants that are likely damaging, we applied two deleterious missense (D-mis) prediction algorithms on published ASD and SPARK de novo variants. Among the 390 de novo missense variants in affected offspring, 43.6% are predicted to be deleterious using CADD score ≥25<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and show 1.28-fold enrichment compared with baseline expectation in the general population (<italic>p</italic>-value = 6.6 × 10<sup>−4</sup> by one-sided exact Poisson test). Using a more strict D-mis prediction algorithm with MPC score ≥2,<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> 8% of de novo missense variants are predicted as deleterious and are enriched 1.88-fold in affected offspring which is comparable with the enrichment of dnLGD variants (<italic>p</italic>-value = 9.9 × 10<sup>−4</sup> by one-sided exact Poisson test). The overall burden of de novo D-mis variants is similar to published studies (Supplementary Data <xref ref-type="media" rid="MOESM4">2</xref>).</p>
<p id="Par7">Variants in constrained genes (pLI ≥ 0.5)<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> explain most of the burden of dnLGD variants and de novo D-mis variants (defined by an MPC score ≥2) in the affected offspring in our study (Supplementary Data <xref ref-type="media" rid="MOESM4">2</xref>,<xref ref-type="media" rid="MOESM1">b</xref>). Consistent with previous findings supporting the female protective model,<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> we observed a nonsignificant trend toward a higher frequency of dnLGD variants in constrained genes in female cases compared with males (0.135/female vs 0.096/male), as well as higher frequency of de novo D-mis variants in female cases (CADD ≥25: 0.416/female vs 0.354/male, MPC ≥2: 0.09/female vs 0.066/male).</p>
<p id="Par8">We also investigated deleterious inherited SNV/indel variants and found a modest excess of transmitted, rare LGD (AF &lt; 0.001 in ExAC v0.3) variants observed only once among parents in our cohort (singletons) in constrained genes with pLI ≥ 0.5 (464 transmitted vs. 402 nontransmitted; rate ratio (RR) = 1.15, <italic>p</italic>-value = 0.038 by binomial test). Over-transmission of rare singleton LGD variants was not observed in genes that are not constrained (RR = 1.03, <italic>p</italic>-value = 0.31 by binomial test). The excess of transmitted singleton LGD variants in constrained genes increased after removing variants observed in the ExAC database (303 transmitted vs. 242 untransmitted; RR = 1.25, <italic>p</italic>-value = 0.010 by binomial test). These results provide further evidence that rare, inherited LGD variants in constrained genes confer increased risk for ASD.<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> We then searched for known haploinsufficient ASD or neurodevelopmental disorder (NDD) genes (SFARI Gene score 1 or 2 or listed in DDG2P and associated with a neurological phenotype<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>) that are disrupted by the rare singleton LGD variants and are transmitted. We found 13 such variants (2 of them on the X chromosome), as compared with 10 variants that are not transmitted (including one on the X chromosome) (Supplementary Data <xref ref-type="media" rid="MOESM5">3</xref>). Manual review of these variants revealed that most of them are not likely pathogenic because they either affect only a subset of transcripts that are not expressed in the majority of tissues,<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> are located close to the 3′ end of the transcript (last 5% of the coding sequence) or are indels that overlap but do not change the sequence of essential splice sites. The results suggest that the rare LGD variants in known ASD/NDD genes have only limited contribution to the overall transmission disequilibrium in this class of variants.</p>
<p id="Par9">By integrating exome sequence read depth and SNP microarray signal intensity data, we identified 273 rare CNVs (occurring with a carrier frequency of ≤1% of the 1379 individuals in the analysis and also appear &lt;1% in 1000 Genomes population and healthy controls<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>) in 206 affected offspring. Of these, 253 CNVs were inherited (0.544/affected offspring) and were on average 194 kb. These inherited CNVs contained an average of 3.7 genes, which reduces to an average of 0.7 genes that are constrained (pLI ≥ 0.5) (Supplementary Data <xref ref-type="media" rid="MOESM6">4</xref>). Similar to the frequency observed in previous studies<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> (~5% within a cohort of affected individuals), we identified 20 de novo CNVs (dnCNVs) (0.043/affected offspring) (Supplementary Data <xref ref-type="media" rid="MOESM7">5</xref>). On average, dnCNVs were larger (1.6 Mb) and contained more total and constrained genes (19 genes, 5.5 constrained genes with a pLI ≥ 0.5).</p>
<p id="Par10">Despite the fact we were underpowered to detect statistically significant burden differences between sexes, we observed a trend toward a 1.8-fold higher burden of dnCNVs in ASD females (0.067/female vs 0.037/male, respectively). In contrast, the frequency of rare, inherited CNVs in ASD females and males were similar (0.551/female vs 0.543/male, respectively). Similar to Sanders et al.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> dnCNVs in female cases also affect more genes than dnCNVs in males (2.3 vs 0.47 genes in dnCNVs per female proband vs per male proband, respectively; <italic>p</italic>-value = 0.013, Kruskal–Wallis test).</p>
<p id="Par11">Of the CNVs detected, six mapped to the chromosome 16p11.2 region (three de novo and three inherited in five families). Four of the six 16p11.2 CNVs occurred at the most common breakpoints (BP4-BP5), occurring in 0.9% of affected offspring, consistent with the expected ASD prevalence.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> Together, the results suggest that the saliva-derived DNA collected in SPARK should provide comparable CNV data to previous studies using DNA derived from whole blood. We also used read-depth and SNP genotypes to identify several chromosomal aneuploidies (Supplementary Fig. <xref ref-type="media" rid="MOESM1">1</xref>), including one case of trisomy 21 (47, XY + 21), one case of Klinefelter syndrome (47, XXY), one case of Turner syndrome (45, X), and one case of uniparental iso-disomy of chromosome 6 (UPiD6).</p>
<p id="Par12">Given their emerging role in genetic risk for ASD and other NDDs, we also assessed postzygotic mosaic mutations<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup> in the SPARK cohort. In parallel, we utilized a previously established method<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and a novel approach to identify likely mosaic SNVs (Methods, Supplementary Figs. <xref ref-type="media" rid="MOESM1">3</xref>–<xref ref-type="media" rid="MOESM1">8</xref>). We identified 65 likely mosaic mutations (0.142/offspring) (Supplementary Data <xref ref-type="media" rid="MOESM8">6</xref>). The majority of these mutations were unique to the mosaic call set; however, 18 were also identified in the main de novo SNV call set with an average alternative allele fraction of 25.4% (Supplementary Data <xref ref-type="media" rid="MOESM8">6</xref>), suggesting that these mutations are likely to have occurred after fertilization. These results indicate that ~10% (65/652) of the total de novo SNVs in the SPARK pilot are of postzygotic origin. Comparing these data to a similar mosaic set from the Simons Simplex Collection (SSC),<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> we found similar mosaic mutation characteristics, despite the fact that different DNA sources, capture reagents, and sequencing instruments were used (Supplementary Fig. <xref ref-type="media" rid="MOESM1">7</xref>). Due to the limited number of mosaic calls, we did not attempt to evaluate mosaic mutation burden. However, we observed that a number of potentially mosaic mutations were in known ASD/NDD genes or genes that are constrained (Supplementary Data <xref ref-type="media" rid="MOESM8">6</xref>). For example, we identified a potential mosaic LGD variant in <italic>MACF1</italic>, which is highly constrained (pLI = 1), plays essential roles in neurodevelopment, functions through the previously implicated Wnt signaling pathway,<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> and has been recently suggested as a candidate gene based on a dnLGD variant in a Japanese ASD cohort.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> In <italic>CREBBP</italic>, which reached genome-wide significance in a recent NDD meta-analysis,<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> we identified a potential mosaic missense variant, in addition to two other germline de novo missense variants in SPARK, adding to the evidence that it is an ASD/NDD risk factor. Future work will help determine the contribution of mosaic mutations in such genes to ASD.</p>
</sec>
<sec id="Sec4">
<title>Genes with a higher mutational burden</title>
<p id="Par13">We assessed genes with multiple dnLGD variants in the SPARK cohort and identified four genes with more than one dnLGD variant (<italic>CHD8</italic>, <italic>FOXP1</italic>, <italic>SHANK3</italic>, and <italic>BRSK2</italic>). <italic>BRSK2</italic> is the only gene with multiple dnLGD variants in SPARK that reached genome-wide significance (<italic>p</italic>-value = 2.3 × 10<sup>−6</sup> by one-sided exact Poisson test, &lt;0.05/20,000 genes), although there was one individual in the Autism Sequencing Consortium (ASC) cohort<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> with a dnLGD variant in <italic>BRSK2</italic> (Table <xref ref-type="table" rid="Tab2">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Variants in four newly statistically significant and constrained (pLI ≥ 0.5) ASD risk genes (<italic>BRSK2, ITSN1, FEZF2</italic>, and <italic>PAX5</italic>) in published and SPARK trios and associated phenotypic information</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>
<bold>Subject ID</bold>
</td><td>
<bold>SP0037695</bold>
</td><td>
<bold>SP0042217</bold>
</td><td>
<bold>08C79336</bold>
</td><td>
<bold>SP0007556</bold>
</td><td>
<bold>SP0025011</bold>
</td><td>
<bold>SP0016887</bold>
</td><td>
<bold>13400.p1</bold>
</td><td>
<bold>13704.p1</bold>
</td><td>
<bold>14637.p1</bold>
</td><td>
<bold>SP0037344</bold>
</td><td>
<bold>11074.p1</bold>
</td><td>
<bold>SP0016232</bold>
</td><td>
<bold>12858.p1</bold>
</td></tr><tr><td>Cohort</td><td>SPARK</td><td>SPARK</td><td>ASC</td><td>SPARK</td><td>SPARK</td><td>SPARK</td><td>SSC</td><td>SSC</td><td>SSC</td><td>SPARK</td><td>SSC</td><td>SPARK</td><td>SSC</td></tr><tr><td>Gene</td><td>
<italic>BRSK2</italic>
</td><td>
<italic>BRSK2</italic>
</td><td>
<italic>BRSK2</italic>
</td><td>
<italic>ITSN1</italic>
</td><td>
<italic>ITSN1</italic>
</td><td>
<italic>ITSN1</italic>
</td><td>
<italic>ITSN1</italic>
</td><td>
<italic>ITSN1</italic>
</td><td>
<italic>ITSN1</italic>
</td><td>
<italic>FEZF2</italic>
</td><td>
<italic>FEZF2</italic>
</td><td>
<italic>PAX5</italic>
</td><td>
<italic>PAX5</italic>
</td></tr><tr><td>Variant</td><td>p.T547fs</td><td>c.951-1G &gt; A</td><td>c.1365-1G &gt; C</td><td>p.P1619L (MPC = 2.03)</td><td>p.P156fs</td><td>p.Q711X</td><td>c.1952 + 1del</td><td>p.E576*</td><td>p.P164Rfs*22</td><td>p.A397fs</td><td>p.R344C (MPC = 3.37)</td><td>p.E113V (MPC = 2.78)</td><td>p.A111fs</td></tr><tr><td>Inheritance</td><td>de novo</td><td>de novo</td><td>de novo</td><td>de novo</td><td>Inherited (paternal)</td><td>Inherited (paternal)</td><td>Inherited (maternal)</td><td>Inherited (paternal)</td><td>Inherited (paternal)</td><td>de novo</td><td>de novo</td><td>de novo</td><td>de novo</td></tr><tr><td>Confirmed by Sanger sequencing?</td><td>YES</td><td>YES</td><td>Not available</td><td>YES</td><td>YES</td><td>YES</td><td>Not available</td><td>Not available</td><td>Not available</td><td>YES</td><td>YES</td><td>YES</td><td>YES</td></tr><tr><td>Sex</td><td>Male</td><td>Male</td><td>Male</td><td>Male</td><td>Male</td><td>Female</td><td>Female</td><td>Male</td><td>Male</td><td>Male</td><td>Male</td><td>Male</td><td>Female</td></tr><tr><td>DSM diagnosis</td><td>ASD</td><td>ASD</td><td>ASD</td><td>Asperger’s disorder</td><td>Asperger’s disorder</td><td>ASD</td><td>Autism</td><td>PDD-NOS</td><td>Autism</td><td>ASD</td><td>Autism</td><td>ASD</td><td>Autism</td></tr><tr><td>Age at evaluation (years)</td><td>8</td><td>19</td><td>5.3</td><td>30</td><td>34</td><td>2</td><td>4.2</td><td>4.3</td><td>5.4</td><td>23</td><td>9</td><td>14</td><td>4</td></tr><tr><td>Medical concerns</td><td>None</td><td>Premature birth (24 weeks), vision/hearing problems (not specified)</td><td>Unknown</td><td>Obesity, vision/hearing problems (not specified)</td><td>None</td><td>None</td><td>Migraines</td><td>None</td><td>None</td><td>None</td><td>None</td><td>Neurological problems (not specified), sleep disorder</td><td>None</td></tr><tr><td>Seizures (TRUE/FALSE)</td><td>FALSE</td><td>TRUE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>Febrile seizures only</td><td>FALSE</td><td>FALSE</td></tr><tr><td>Intellectual Disability (TRUE/FALSE), IQ (if known)</td><td>TRUE</td><td>TRUE, ≤25</td><td>Unknown</td><td>FALSE, ≥129</td><td>FALSE</td><td>FALSE</td><td>FALSE, FSIQ = 116</td><td>FALSE FSIQ = 91</td><td>TRUE− mild, FSIQ = 63</td><td>FALSE</td><td>TRUE, FSIQ = 68</td><td>TRUE, 55–69</td><td>FALSE, FSIQ = 91</td></tr><tr><td>Language level (at age of evaluation)</td><td>Delayed, single words</td><td>Delayed, no words</td><td>Delayed</td><td>Fluent speech (sentences)</td><td>Fluent speech (sentences)</td><td>Delayed, single words</td><td>Delayed, phrase speech (ADOS mod. 2)</td><td>Delayed, phrase speech (ADOS mod. 2)</td><td>Delayed, phrase speech (ADOS mod. 2)</td><td>Unknown</td><td>Fluent speech (sentences; ADOS mod. 3)</td><td>Delayed, no words</td><td>Delayed, phrase speech (ADOS mod. 2)</td></tr><tr><td>Language regression (TRUE/FALSE)</td><td>FALSE</td><td>FALSE</td><td>Unknown</td><td>FALSE</td><td>Unknown</td><td>TRUE</td><td>FALSE</td><td>TRUE</td><td>FALSE</td><td>Unknown</td><td>TRUE</td><td>TRUE</td><td>TRUE</td></tr><tr><td>Co-morbid psychological diagnoses</td><td>Learning disorder, motor skills delay, speech articulation problems, feeding disorder</td><td>Motor skills delay, speech articulation problems, feeding disorder, encopresis, enuresis</td><td>None</td><td>Attention or behavior problems—not specified, mood or anxiety problems—not specified, feeding disorder</td><td>Attention or behavior problems—not specified, OCD</td><td>Feeding disorder</td><td>Anxiety</td><td>None</td><td>None</td><td>None</td><td>None</td><td>Learning disorder, feeding disorder</td><td>None</td></tr><tr><td>Early motor delay (TRUE/FALSE)</td><td>FALSE</td><td>TRUE</td><td>FALSE</td><td>FALSE</td><td>Unknown</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>FALSE</td><td>Unknown</td><td>FALSE</td><td>FALSE</td><td>FALSE</td></tr></tbody></table><table-wrap-foot><p>All damaging variants in SPARK participants within these genes have been confirmed with Sanger sequencing. Damaging variants in <italic>PAX5</italic> and <italic>FEZF2</italic> in the SSC were previously validated.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> MPC scores are listed for missense mutations. All phenotypic information for SPARK participants was collected online</p></table-wrap-foot></table-wrap></p>
<p id="Par14">To increase the statistical power to identify new ASD genes, we performed a meta-analysis of de novo variants in 4773 published ASD trios<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup> and 465 SPARK trios using TADA<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> (Methods). In this analysis, we included dnLGD variants and de novo D-mis variants, which we defined as those that have a CADD score ≥25.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> The TADA analysis presumes a model of genetic architecture compatible with the observed burden and recurrence of de novo damaging variants and assigns a false discovery rate (FDR) <italic>q</italic>-value for each gene based on the number of damaging variants and baseline mutation rates. We identified 67 genes with an FDR threshold of ≤0.1. Of these, there are 26 genes that also harbored a damaging variant in SPARK, most of which are already known ASD/NDD genes. There are six genes (<italic>BRSK2</italic>, <italic>ITSN1</italic>, <italic>PAX5, FEZF2, DMWD</italic>, and <italic>CPZ</italic>) that reached an FDR threshold of 0.1 only after the inclusion of de novo variants from SPARK (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The association signal for <italic>DMWD</italic> was driven by two LGD variants but the gene is not constrained (pLI = 0), so this gene may be a false positive.<fig id="Fig1"><label>Fig. 1</label><caption><p>Meta-analysis using the TADA framework identifies 34 genes with a false discovery rate (FDR) of ≤0.2. Known ASD genes are defined as those with SFARI Gene<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> score ≤2 or implicated in a previous TADA meta-analysis (FDR ≤ 0.1)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> and known NDD genes are those listed in the DDG2P database<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> and are colored orange. Deleterious missense (D-mis) variants are defined by CADD score ≥25. A total of 34 genes with at least one de novo damaging variant observed in SPARK pilot trios achieve an FDR ≤ 0.2 after meta-analysis with published trios (total <italic>n</italic> = 5238). Fourteen genes are not classified as known ASD or NDD genes. Six genes (<italic>BRSK2, ITSN1, FEZF2, PAX5, DMWD</italic>, and <italic>CPZ</italic>) that have an FDR ≤ 0.1 only after inclusion of SPARK de novo variants are highlighted. The asterisk symbol indicates genes that are not constrained (pLI &lt; 0.5)</p></caption><graphic id="d29e4022" xlink:href="41525_2019_93_Fig1_HTML"></graphic></fig></p>
<p id="Par15">Of the 34 genes listed in Fig. <xref ref-type="fig" rid="Fig1">1</xref>, only <italic>BRSK2</italic> meets genome-wide significance as a new ASD risk gene. All four individuals in SPARK, ASC and the SSC with de novo functional variants in <italic>BRSK2</italic> are males with cognitive impairment and severe speech delay (Table <xref ref-type="table" rid="Tab2">2</xref>). <italic>MBD5</italic> and <italic>IRF2BPL</italic> reached an FDR value of ≤0.1 in a previous meta-analysis but not significant in our analysis of published de novo variants,<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> because the previous study also included evidence from de novo CNVs and deleterious variants of unknown inheritance from a case-control sample in that analysis. <italic>MBD5</italic>, as well as <italic>QRICH1, SLC6A8</italic>, and <italic>RERE</italic> are known NDD risk genes in the latest DDG2P database.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup></p>
<p id="Par16">In our TADA results, we further broadened our focus on genes that harbored damaging variants in the SPARK data and those that had a FDR ≤ 0.2 (Supplementary Data <xref ref-type="media" rid="MOESM9">7</xref>). When the TADA analysis is restricted to genes harboring damaging variants in SPARK with an FDR ≤ 0.2, we identified 34 genes (Fig. <xref ref-type="fig" rid="Fig1">1</xref>), of which 21 have a known role in ASD or NDDs. We also incorporated inherited variants and CNVs from the SPARK families into the TADA analysis, but did not find additional newly significant genes.</p>
<p id="Par17">We then searched for additional supporting evidence for a role of these genes in ASD and NDDs, including other deleterious variants in previous studies and case reports not included in the meta-analysis, membership in gene sets previously associated with ASD,<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup> and published functional studies (Supplementary Data <xref ref-type="media" rid="MOESM10">8</xref>). Recent studies have reported additional individuals with ASD and/or NDD with de novo damaging variants in these genes including <italic>BRSK2</italic>,<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>
<italic>PAX5</italic>,<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>
<italic>NR4A2</italic>,<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>
<italic>RALGAPB</italic>,<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup> and <italic>DPP6</italic>.<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup></p>
<p id="Par18">In addition to multiple deleterious variants in these candidate ASD risk genes, we also found evidence that they function in biological pathways previously linked to ASD. For example, mRNA translation of <italic>BRSK2, ITSN1</italic>, and <italic>RALGAPB</italic> in neurons is predicted to be regulated by FMR1 protein.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> In addition, <italic>ITSN1</italic> and <italic>DPP6</italic> are part of the postsynaptic density components in human neocortex.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>
<italic>PAX5</italic> and <italic>FEZF2</italic> are involved in transcription regulation during central nervous system development.<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>
<italic>KDM1B</italic> is a known chromatin modifier, and <italic>EGR3</italic> has been implicated in neurodevelopment.<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup></p>
<p id="Par19">We also searched rare singleton inherited LGD variants of these newly significant genes in SPARK and published SSC data, and identified five additional cases (three in SSC, two in SPARK) carrying inherited LGD variants of <italic>ITSN1</italic> that likely cause loss of gene function. Interestingly, of the six ASD cases with LGD variants in <italic>ITSN1</italic>, five do not have intellectual disability (Table <xref ref-type="table" rid="Tab2">2</xref>). The less severe phenotype and inheritance from unaffected parents are consistent with the modest effect size, although future studies will help determine if <italic>ITSN1</italic> is a bona fide ASD risk gene. Furthermore, in ASC case-control samples,<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> LGD variants in <italic>ITSN1</italic> were also identified in the controls (three in 5397 ASC controls and comparable with the cumulative AF of 2.5e−4 in gnomAD v2.1), although they were still overrepresented in cases (two in 1601 cases).</p>
</sec>
<sec id="Sec5">
<title>Functional network analysis and gene expression patterns in candidate ASD risk genes</title>
<p id="Par20">To relate the candidate ASD risk genes identified in our TADA analysis to previous knowledge of integrated gene networks in ASD, we scored genes with a TADA FDR ≤ 0.2 and not currently listed in SFARI Gene using forecASD, a new ensemble classifier that integrates spatiotemporal gene expression, heterogeneous network data, and previous gene-level predictors of ASD association.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> Using forecASD, we derived a single score that ranks the evidence for each gene to be involved in ASD risk. Using this approach, we identified ten genes (<italic>RNF25, DMWD, CLCN4, ITSN1, CPZ, SH3RF3, EGR3, RALGAPB, KDM1B</italic>, and <italic>BRSK2</italic>) that have a TADA FDR ≤ 0.2 and were not listed in the SFARI Gene database. These genes have significantly elevated forecASD scores (<italic>p</italic>-value = 0.007, <italic>Z</italic>-test in logistic regression model controlling for contribution of previous TADA scores; Supplementary Fig. <xref ref-type="media" rid="MOESM1">9</xref>). Furthermore, two predictive features in forecASD that summarize brain expression support and network support are also found to be significantly elevated over the genome background in the set of these ten genes (<italic>p</italic>-value = 0.015 and <italic>p</italic>-value = 0.03, respectively, Wilcoxon test; see Supplementary Fig. <xref ref-type="media" rid="MOESM1">9</xref>). Importantly, neither of these metrics uses genetic data directly, so these genes collectively have support across the three independent and distinct domains of genetic, network, and brain expression evidence. These statistical associations are conservative estimates because they compare the distribution of evidence scores among the candidate genes described here to the remainder of the genome, which includes well-established ASD genes. Eight of these genes, <italic>BRSK2, KDM1B, RALGAPB, EGR3, SH3RF3, CPZ, ITSN1</italic>, and <italic>CLCN4</italic> fall in the top decile of forecASD scores (the top decile being a recommended cutoff used to define probable ASD risk genes), supporting these genes as having similar properties overall compared with known ASD risk genes.</p>
<p id="Par21">To illustrate the network context of these eight candidate ASD risk genes, we clustered them along with genes scoring within the top decile of forecASD (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>). Network analysis yielded ten tightly connected clusters with distinct biological functions (Supplementary Data <xref ref-type="media" rid="MOESM11">9</xref>). Several genes were assigned to clusters that showed enrichment for gene sets consistent with their known functions, including <italic>KDM1B</italic>,<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>
<italic>BRSK2</italic>,<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> and <italic>ITSN1</italic><sup><xref ref-type="bibr" rid="CR43">43</xref></sup> consistent with published functional evidence (Supplementary Data <xref ref-type="media" rid="MOESM10">8</xref>). In a subsequent analysis, the interactions between known and novel ASD candidate risk genes were visualized (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>). This subnetwork was significantly interconnected (<italic>p</italic>-value = 5.0 × 10<sup>−179</sup> by hypergeometric test), with novel genes showing significantly more functional associations with known ASD candidate risk genes than expected by chance (<italic>p</italic>-value = 0.005 by hypergeometric test).<fig id="Fig2"><label>Fig. 2</label><caption><p>Network analysis and gene expression of candidate ASD risk genes. <bold>a</bold> STRING networks of forecASD genes, <bold>b</bold> STRING networks of known ASD genes, and <bold>c</bold> gene expression of human fetal cortex at postconceptual weeks (PCW) 15–16. Known ASD genes are defined as those with a SFARI Gene scores<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> ≤2 (84 genes, indicated as SFARI) or implicated in a previous TADA meta-analysis<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> at an FDR ≤ 0.1 (65 genes, indicated as TADA). The enrichment for each gene was measured by the <italic>t</italic>-statistics comparing the expression level in each layer against all other layers. The enrichment of a gene set is the mean of <italic>t</italic>-statistics of its genes. Two candidate ASD risk genes (<italic>PAX5</italic> and <italic>KDM1B</italic>) are not shown due to the low expression levels in human developing cortex (RPKM &lt;1 for at least 20% available neocortical samples in BrainSpan<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>). Data were extracted from Supplementary Tables of Parikshak et al.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> Laminae abbreviations: marginal zone (MZ), outer/inner cortical plate (CPo/CPi), subplate (SP), intermediate zone (IZ), outer/inner subventricular zone (SZo/SZi), ventricular zone (VZ)</p></caption><graphic id="d29e4345" xlink:href="41525_2019_93_Fig2_HTML"></graphic></fig></p>
<p id="Par22">Using coexpression networks seeded by high-confidence ASD risk genes, a previous study found that cortical projection neurons in layers V and VI of the human midfetal prefrontal and primary motor-somatosensory cortex are a key point of convergence for ASD risk genes.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> Another study also showed that unbiased gene co-expression networks overrepresented with candidate ASD risk genes are more highly expressed in the cortical plate and subplate laminae of the developing human cortex, which will go on to form mature layers II–VI of the cerebral cortex.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> One of the newly statistically significant genes we identified, <italic>FEZF2</italic>, is a powerful master regulator gene critical for establishing corticospinal neurons,<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> which connect layer Vb of the cortex to the spinal cord, and is known to be expressed in the putative layer V in the late mid-fetal human cortex.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup></p>
<p id="Par23">We evaluated gene expression of the candidate ASD risk genes identified by either the TADA meta-analysis and forecASD with regard to cortical layer specificity in the human developing brain.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> Ten of these genes (<italic>BRSK2, ITSN1, FEZF2, RALGAPB, NR4A2, EGR3</italic>, <italic>DPP6, CPZ, SH3RF3</italic>, and <italic>CLCN4</italic>) have expression data in developing fetal human cortex, and similar to Parikshak et al.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> they show a trend of increased expression at postconceptual week (PCW) 15–16 (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>) and PCW 21 (Supplementary Fig. <xref ref-type="media" rid="MOESM1">10</xref>) in the cortical plate and subplate laminae, which will form layers II–VI of the mature cerebral cortex. The mean of <italic>t</italic>-statistics of these ten genes in the inner cortical plate (CPi) and subplate (SP) are greater than two standard deviations (SD) from the mean of randomly selected genes matched for gene length and GC content (<italic>P</italic> &lt; 0.01 by simulation).</p>
<p id="Par24">We further evaluated cell-type specificity using recently published single-cell RNA-seq data from fetal and adult mouse and human brains<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> (Supplementary Figs. <xref ref-type="media" rid="MOESM1">11</xref> and <xref ref-type="media" rid="MOESM1">12</xref>), and found the expression specificity of these candidate ASD risk genes is highest in pyramidal neurons in the mouse hippocampus CA1 region with an enrichment of 3.4 SD from the bootstrapped mean (<italic>p</italic>-value = 9.6e−3 by simulations controlling gene length and GC content, Supplementary Fig. <xref ref-type="media" rid="MOESM1">11</xref>). The enrichment in pyramidal neurons is also observed in the hippocampus CA1 region in human (2.4 SD above the bootstrapped mean, <italic>p</italic>-value = 0.02 by simulation) using recently published human single nucleus RNA-seq data.<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> These results are consistent with a previous study showing that ASD protein–protein interaction networks related to the 16p11.2 CNV display significantly enriched expression during mid-fetal development as well as early childhood in cerebral cortex.<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> Taken together, we find that the candidate ASD risk genes identified in this study demonstrate differential expression patterns similar to that of known ASD risk genes, providing further support that these genes function in similar biological pathways and mechanisms as known ASD risk genes.</p>
</sec>
<sec id="Sec6">
<title>Diagnostic yield in SPARK</title>
<p id="Par25">Families in the pilot study were selected without regard to genetic diagnosis. Thirteen of the 457 families self-reported a genetic diagnosis, and all were confirmed by our analyses and serve as positive controls to validate our genomic analyses (Supplementary Data <xref ref-type="media" rid="MOESM12">10</xref>). For the remaining 444 families, we identified 50 (10.4%) deleterious genetic variants (8 dnCNVs, 14 inherited CNVs, 23 de novo SNVs or indels, 3 inherited LGD variants and 2 chromosomal aneuploidies) in known ASD risk genes or loci in 49 affected individuals (Supplementary Data <xref ref-type="media" rid="MOESM12">10</xref>). We also identified an additional 19 likely deleterious genetic variants (1 dnCNV, 1 inherited CNV, 14 de novo SNVs and 3 inherited SNVs) in possible ASD risk genes or loci in an additional 14 individuals (3.4%). For all cases, we defined deleterious ASD-associated variants as those meeting likely pathogenic or pathogenic criteria according to ACMG standards.<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> We defined possible ASD-associated variants as either SNVs that are de novo missense variants that affect known NDD or ASD genes and have an MPC score<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> ≥2, loss-of-function variants that disrupt possible NDD or ASD genes, or CNVs that delete one or more possible NDD or ASD genes or duplicate known ASD or NDD loci. Possible ASD genes include those that are newly significant in this study (FDR ≤ 0.2) with independent evidence from literature, or genes implicated by other studies with multiple LGD variants found in affected ASD and NDD cases (summarized Supplementary Data <xref ref-type="media" rid="MOESM10">8</xref>). We did not search for or discover any incidental findings unrelated to ASD in these families. When DNA was available, ASD-associated genetic findings were confirmed by Sanger sequencing or chromosome microarray, and genetic results were returned to the families (<italic>n</italic> = 28).</p>
</sec>
</sec>
<sec id="Sec7" sec-type="discussion">
<title>Discussion</title>
<p id="Par26">Overall, the genomic characterization of 457 ASD families (418 simplex and 39 multiplex) in SPARK implicates a number of candidate risk genes in ASD that converge on similar biological networks as known ASD risk genes. We identified a returnable genetic result related to ASD in 10.4% of affected offspring and have begun returning individual genetic results to the families after confirming results in a clinical laboratory. Not surprisingly, our diagnostic yield was highest in affected individuals who also report presence of seizures (27%). The yield in individuals who also report intellectual disability was also higher (20%) than the overall cohort.</p>
<p id="Par27">In our analysis, our diagnostic yield in affected offspring in multiplex families (15.2%) was slightly higher than affected offspring in simplex families (10.1%). Interestingly, the genetic findings in multiplex families rarely explained ASD in all affected family members (Supplementary Fig. <xref ref-type="media" rid="MOESM1">13</xref>), similar to previous studies that have also found affected siblings with discordant mutations.<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup> For example, in a family with an affected father and three affected children, the most severely affected child harbored a dnLGD in <italic>ADNP</italic>. No other family member carried this variant or any other identifiable contributing variant. In another pedigree, an affected male child with an affected father inherited a 15q11.2 BP1-BP2 deletion from a mother who does not report an ASD diagnosis, but we found no contributing variant in the affected father. We also identified eight families in which there was greater than one contributing variant, even in families in which we were unable to identify contributing variants in all affected offspring. In one family with two affected children, the female child inherited a 1q21.1 CNV from an unaffected mother and also harbored a dnLGD in <italic>RALGAPB</italic>. However, the affected male child did not harbor either of these variants and the CNV identified, like many potentially pathogenic variants, is known to be variably expressive. Future studies with larger sample sizes will allow for a more robust comparison of the genetic architecture of ASD in simplex vs. multiplex families.</p>
<p id="Par28">Over time, we expect the diagnostic yield in SPARK to increase as more individuals with ASD are studied and as additional genetic risk factors are identified. For example, we identified LGD variants in <italic>MEIS2</italic> and <italic>AKAP10</italic> and deletions of the <italic>NFIB, DLL1</italic>, and <italic>HNRNPD</italic> genes. Although these genes did not reach statistical significance in our TADA meta-analysis, their role in ASD is supported by multiple mutations in the literature, and they likely represent other candidate ASD risk genes (Supplementary Data <xref ref-type="media" rid="MOESM10">8</xref>). We interpreted those variants as possible contributors to ASD in those individuals. The genetic findings in those cases will be confirmed and returned in the future if and when these genes are established as ASD risk genes.</p>
<p id="Par29">Using a systems biology approach, we demonstrated that the newly statistically significant and candidate ASD risk genes identified in this analysis are well-supported beyond genetic association and are predicted to be ASD risk genes based on a variety of functional properties, including patterns of spatiotemporal gene expression in the brain and protein network connectivity. <italic>BRSK2</italic> and seven of the candidate ASD risk genes scored in the top decile of forecASD, an integrator of published functional evidence for ASD risk genes (Supplementary Fig. <xref ref-type="media" rid="MOESM1">9</xref>). The genes localized to network clusters representing processes critical for neurodevelopment (Fig. <xref ref-type="fig" rid="Fig2">2</xref>), including chromatin modification (<italic>KDM1B</italic>), neuronal polarity<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> (<italic>BRSK2</italic>), and neuronal migration of pyramidal neurons<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> (<italic>ITSN1</italic>). The candidate ASD risk genes also showed significant over-connectivity to known ASD risk genes (<italic>p</italic>-value = 0.005 by hypergeometric test, Fig. <xref ref-type="fig" rid="Fig2">2b</xref>). Together, the TADA genetic association analysis coupled with the supporting functional and network-level data triangulate these genes as being robust and biologically plausible contributors to ASD risk.</p>
<p id="Par30">Despite the limited sample size in this pilot study, we were able to identify four newly statistically significant ASD genes. Power analysis using a simulation-based approach confirmed that the observed yield is expected given the presumed genetic architecture in the TADA analysis (Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>). We expect to identify ~70–75% of all ASD risk genes in the future that meet a similar FDR threshold (0.1–0.2) when we reach SPARK’s goal of sequencing 50,000 complete trios (Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>). Other analyses of large cohorts in ASD are underway, including a recent analysis of ~12,000 individuals with ASD.<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> This study, which used a mixture of family-based and case-control data, found statistical support for 99 ASD risk genes, increasing the number of ASD risk genes from 65.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> Future meta-analyses of both SPARK data and other ASD cohort data are planned to maximize ASD risk gene discovery.</p>
<p id="Par31">For many genes identified with de novo damaging variants, inherited loss-of-function variants in affected individuals were not found (Kosmicki et al. <sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and this study), suggesting our current knowledge about ASD risk genes is biased toward those with high penetrance. Future studies with larger sample sizes will be needed to identify and validate additional risk genes of lower penetrance that confer inherited ASD risk.</p>
<p id="Par32">Altogether, these data suggest that the methods used to ascertain individuals with ASD, saliva collection, and genomic data are of high quality, and future analysis of the tens of thousands of families enrolling in SPARK will significantly contribute to our understanding of the genetic basis of ASD. By returning genetic results to participants, we expect to increase engagement and increase the number of recontactable participants for genetically targeted clinical research and trials.</p>
</sec>
<sec id="Sec8">
<title>Methods</title>
<sec id="Sec9">
<title>Participant recruitment, phenotyping, and DNA sequencing</title>
<p id="Par33">All participants were recruited to SPARK under a centralized IRB protocol (Western IRB Protocol #20151664). All participants provided written informed consent to take part in the study. Written informed consent was obtained from all legal guardians or parents for all participants age 18 and younger and all participants age 18 and older who have a legal guardian. Assent was also obtained from dependent participants age 10 and older. Participants are asked to fill out questionnaires online as described here: <ext-link ext-link-type="uri" xlink:href="https://www.sfari.org/spark-phenotypic-measures/">https://www.sfari.org/spark-phenotypic-measures/</ext-link>. Families are classified as multiplex if the initial individual with ASD registered in the study has a first-degree family member with ASD, as indicated either by enrollment or survey report.</p>
<p id="Par34">Essential phenotypic information was curated across language and motor development, co-morbidities, and Repetitive Behavior Scale-Revised,<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> Social Communication Questionnaire-Lifetime<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> and Developmental Coordination Disorder Questionnaire score<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> (Table <xref ref-type="table" rid="Tab2">2</xref>). In SSC, all phenotype details were determined through clinic evaluation and interview; specifically, language delay was defined by Autism Diagnostic Observation Schedule module (1–4) per age,<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> and regression was determined from the Autism Diagnostic Interview-Revised.<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> For SPARK, all variables were taken from parent report. It was noted that rates of language disorder and psychiatric co-morbidities are lower in SSC likely due to DSM-IV diagnostic practice at the time.</p>
<p id="Par35">Saliva was collected using the OGD-500 kit (DNA Genotek) and DNA was extracted in a CLIA-certified laboratory at the Baylor Miraca Genetics Laboratories (Houston, TX) or PreventionGenetics (Marshfield, WI). Exome capture was performed using VCRome and the spike-in probe set PKv2 at the Baylor College of Medicine Human Genome Sequencing Center (Houston, TX). Captured exome libraries were sequenced using the Illumina HiSeq platform in 100 bp paired end reads. Samples were sequenced to a minimum standard of &gt;85% of target covered at 20×, and on average, 96% of the target was sequenced to 20×. The Illumina HumanCoreExome (550K SNP sites) array was used for genotyping.</p>
</sec>
<sec id="Sec10">
<title>Read alignment and QC</title>
<p id="Par36">Postsequencing reads were aligned to build 37 of the human genome using bwa version 0.6.2-r126,<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> duplicates were marked using Picard version 1.93 MarkDuplicates, and indels were realigned using GATK<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> version 2.5-2-gf57256b IndelRealigner. Quality checks were performed on the BAM files using SAMTools<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> version 1.3.1 flagstat and Picard version 2.5.0 CalculateHsMetrics. Overall, 98 ± 1.8% of the reads mapped to the genome, 96 ± 2.3% of the reads were properly paired reads, and 87 ± 15% of targeted regions had ≥10× coverage.</p>
<p id="Par37">KING<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> was used for relatedness inference based on the genotype of exome SNPs (MAF &gt;0.01). Estimated kinship coefficient and number of SNPs with zero shared alleles (IBS0) between a pair of individuals were plotted. Parent–offspring, sibling pairs, and unrelated pairs can be distinguished as separate clusters on the scatterplot (Supplementary Fig <xref ref-type="media" rid="MOESM1">1</xref>). One outlier parent–offspring pair (SP0002452 and mother) showed higher than expected IBS0 and was caused by parental chr6 iso-UPD. Pairwise scatterplots of heterozygotes to homozygotes (het/hom) ratio of chromosome X, sequencing depth of chromosome X and Y normalized by the mean depth of autosomes were used for sex check. Two samples with sex chromosome aneuploidy were identified as outliers in the scatterplot (Supplementary Fig. <xref ref-type="media" rid="MOESM1">2</xref>).</p>
</sec>
<sec id="Sec11">
<title>Variant calling</title>
<sec id="Sec12">
<title>De novo SNV/indel detection</title>
<p id="Par38">De novo sequence variants were called by three groups—University of Washington (UW), Simons Foundation (SF), Columbia University Medical Center (CUMC)—according to the methods below.</p>
</sec>
<sec id="Sec13">
<title>UW</title>
<p id="Par39">Variants were called from whole exome sequence (WES) using FreeBayes<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> and GATK.<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> FreeBayes version v1.1.0-3-g961e5f3 was used with the following parameters: –use-best-n-alleles 4 -C 2 -m 20 -q 20; and GATK version 3.7 HaplotypeCaller was used with the following parameters: -A AlleleBalanceBySample -A DepthPerAlleleBySample -A MappingQualityZeroBySample -A StrandBiasBySample -A Coverage -A FisherStrand -A HaplotypeScore -A MappingQualityRankSumTest -A MappingQualityZero -A QualByDepth -A RMSMappingQuality -A ReadPosRankSumTest -A VariantType. Postcalling bcftools<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> version 1.3.1 norm was used with the following parameters -c e -O z -s -m –both. We identified candidate de novo calls based on the intersection of FreeBayes and GATK VCF files and identifying variants present in offspring but not in parents. We required a minimum of ten sequence reads in all members of the parent–offspring trio; an allele balance &gt;0.25 and a PHRED quality &gt;20 for both FreeBayes and GATK variants.</p>
</sec>
<sec id="Sec14">
<title>SF</title>
<p id="Par40">Sequence data were preprocessed using GATK best practices and variant calls were predicted using three variant callers: GATK v3.6,<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> FreeBayes v1.1.0-441, and Platypus v0.8.1-0.<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> GATK: gVCF files were generated for each sample with GATK HaplotypeCaller (minimum confidence thresholds for calling and emitting was set to 30 and 10, respectively); joint variant calls were performed using GATK GenotypeGVCFs with the recommended default hard filters. For SNPs, we filtered out: QD &lt;2.0 || FS &gt;60.0 || MQ &lt;40.0 || MQRankSum &lt;−12.5 || ReadPosRankSum &lt;−8.0. For indels, we filtered out: QD &lt;2.0 || FS &gt;200.0 || ReadPosRankSum &lt;−20.0. FreeBayes: variants were called with default settings for optimal genotyping of indels in lower-complexity sequence. The final data set included candidate calls with a quality of 5 or greater. Platypus: variant calling was performed with local assembly analysis when at most ten haplotypes were allowed. Variants were filtered out for allele bias (<italic>p</italic>-value &lt; 0.0001), bad reads (&gt;0.9), sequence complexity (&gt;0.99) and RMSMQ (&lt;20); other filters were applied on estimated haplotype population frequency (FR), total coverage at the locus (TC) and phred-scaled quality of reference allele (QUAL): (FR[0] &lt; = 0.5 and TC &lt; 4 and QUAL &lt; 20),or (TC &lt; 13 and QUAL &lt; 10),or (FR[0] &gt; 0.5 and TC &lt; 4 and QUAL &lt; 50). For each variant caller, a variant was identified as a candidate de novo variant if the variant was called in the proband and it occurred only once in the cohort, with an alternative allele fraction between 0.2 and 0.8. Both parents were required to have the homozygous reference genotype at the de novo locus. Read coverage of the variant locus had to be at least ten reads in each sample in the trio. De novo candidate variants were classified by DNMFilter algorithm<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> that was retrained with the SSC data set<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>: 1800 de novo mutations identified by both Iossifov et al.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> and Krumm et al.,<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> 1104 validated SNVs and indels from both studies and 400 variants that failed validation. We also randomly selected ~3000 negative examples from the pool of all SSC variants that were not confirmed to be de novo. After merging de novo candidate variants from three variant callers, candidate de novos were considered if they occurred only once in the cohort, passed hard filters, and had assigned de novo probability greater than 0.88 for SNVs and greater than 0.0045 for small indels. In the latter case, the total parental alternative allele count &lt;3 reads.</p>
</sec>
<sec id="Sec15">
<title>CUMC</title>
<p id="Par41">Variants were called from aligned sequence data using GATK HaplotyperCaller to generate individual level gVCF files. All samples in the cohort were then jointly genotyped and have variant quality recalibrated by GATK v3.8.<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> A variant present in the offspring with homozygous reference genotypes in both parents was considered to be a potential de novo variant. We used a series of filters to identify de novo variants. Briefly, we included variants that passed VQSR filter (tranche ≤ 99.7 for SNVs and ≤99.0 for indels) and had GATK’s Fisher Strand ≤ 25, quality by depth ≥2. We required the candidate de novo variants in probands to have ≥5 reads supporting the alternative allele, ≥20% alternative allele fraction, Phred-scaled genotype likelihood ≥60 (GQ), and population AF ≤0.1% in ExAC; and required both parents to have ≥10 reference reads, &lt;5% alternative allele fraction, and GQ ≥ 30.</p>
</sec>
<sec id="Sec16">
<title>De novo SNV/indel consensus call set and annotation</title>
<p id="Par42">De novo variants were independently called by three centers—UW, SF, CUMC. De novo variants called by all three groups were included in the final list by default. Those called by one or two groups were manually evaluated and included in the final list if consensus was reached among all groups after discussion and manual inspection with IGV plots. Variants were annotated by ANNOVAR<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> based on GENCODE Basic v19.<sup><xref ref-type="bibr" rid="CR73">73</xref></sup> Candidate variants in the ACMG secondary findings v2 59 gene list<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> (except <italic>PTEN</italic>, <italic>TSC1</italic>, and <italic>TSC2</italic>) were excluded. Coding de novo variants—nonsense, missense, or synonymous SNVs, frameshift or nonframeshift indels, and splicing site variants—were annotated. De novo variants were also annotated with snpEff version 4.1g<sup><xref ref-type="bibr" rid="CR75">75</xref></sup> (reference GRCh37.75), SFARI Gene scores (version q1, 2018, <ext-link ext-link-type="uri" xlink:href="https://gene.sfari.org/database/gene-scoring/">https://gene.sfari.org/database/gene-scoring/</ext-link>), CADD,<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> MPC<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> and findings from Deciphering Developmental Disorders project (gene2phenotype).<sup><xref ref-type="bibr" rid="CR16">16</xref></sup></p>
</sec>
<sec id="Sec17">
<title>Inherited singleton variants</title>
<p id="Par43">We first performed following filtering on individual genotypes. We required minimal read-depth ≥10 and GQ ≥30, required allelic balance &lt;0.1 for homozygotes reference, &gt;0.9 for homozygotes alternative, and 0.3–0.7 for heterozygotes SNVs (0.25–0.75 for heterozygotes indels). Genotype calls not passing those criteria were set to missing. Then we removed variants having missing genotypes in &gt;25% of founders. We focused analysis on singleton variants in which the alternative allele was only seen in one parent in the data. We calibrated GATK’s VQS LOD score for SNV and indels separately such that synonymous singleton SNVs and nonframeshift singleton indels were transmitted 50% of the time (Supplementary Fig. <xref ref-type="media" rid="MOESM1">14</xref>) The resulting VQS LOD score cutoffs are −1.85 for SNVs and −1.51 for indels. As mentioned in the Results section, inherited LGD variants are less likely to cause a complete loss of function to the gene. To prioritize inherited LGD variants, we require the variant to be annotated as HC (high-confidence) by LOFTEE v0.3<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> using default parameters in &gt;60% of the GENCODE transcripts.</p>
</sec>
<sec id="Sec18">
<title>Identification of mosaic mutations</title>
<p id="Par44">Mosaic SNVs were independently called by two centers—Oregon Health &amp; Science University (OHSU) and CUMC. The OHSU approach was previously published<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and utilized a binomial deviation and logistic regression model to score candidate mosaic variants. The CUMC approach used a novel approach that was based on a beta-binomial deviation and an FDR based approach to determine per site thresholds.</p>
</sec>
<sec id="Sec19">
<title>OHSU</title>
<p id="Par45">SNVs were called as previously described.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> In brief, pileups were generated using SAMtools (v 1.1) with BAQ disabled and mapQ 29 (<italic>samtools mpileup –B –q 29 –d 1500</italic>) on processed BAMs. Variants were called on individual samples using VarScan 2.3.2, LoFreq 2.1.1 and an in-house mpileup parsing script (mPUP). Additional parameters for Varscan included: –<italic>min-var-freq 1</italic> <italic>×</italic> <italic>10</italic><sup><italic>−15</italic></sup>
<italic>–p-value 0.1</italic>. Per sample caller outputs were combined and annotated using ANNOVAR (03/22/15 release) with databases: Refseq genes (obtained 03/2017), segmental duplications (UCSC track genomicSuperDups, obtained 03/25/2015), repetitive regions (UCSC track simpleRepeat and hg19_rmsk, obtained 03/25/2015), Exome Aggregation Consortium (ExAC) release 0.3 (obtained 11/29/2015), Exome Sequencing Project (ESP) 6500 (obtained 12/22/2014), and 1000 Genomes Phase 3 version 5 (obtained 12-16-2014).</p>
<p id="Par46">Variants were filtered based on the best practices established in Krupp et al.:<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> (1) variant must be exonic or disrupt a canonical splice site, (2) have a population frequency of ≤0.5%, (3) have at least five alternative reads, (4) not be in a known segmental duplication or repetitive regions (SDTRF), (5) called by at least two variant callers, (6) SPARK cohort count ≤1 and SSC cohort count ≤2, (7) variant read mismatch ≤3, and (8) allele fraction upper 90% confidence interval ≤0.05. For a variant to be considered de novo, parental alternative allele count must be ≤4 reads. De novo variants were considered to be candidate mosaic variants if: (1) the probability the allele fraction significantly deviated from heterozygous (PHET) was ≤0.001, (2) the allele fraction upper 90% confidence interval was &lt;0.4, and (3) a logistic regression model score was ≥0.518.</p>
</sec>
<sec id="Sec20">
<title>CUMC</title>
<p id="Par47">SNVs were called on a per-trio basis using SAMtools (v1.3.1-42) and BCFtools (v1.3.1–174). We generated trio VCF files using samtools ‘<italic>mpileup’</italic> command with options <italic>‘–q 20 –Q 13</italic>’ corresponding to mapQ and baseQ thresholds of 20 and 13 respectively, followed by bcftools ‘<italic>call’</italic> with option ‘<italic>–p 1.1</italic>’ to expand the set of variant positions to be evaluated for mosaicism. In contrast to the OHSU pipeline, BAQ was used to potentially reduce false positive SNV calls caused by misalignments.<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> To identify de novo variants from trio VCF files, we selected for sites with (i) a minimum of six reads supporting the alternate allele in the proband and (ii) for parents, a minimum depth of ten reads and 0 alternate allele read support. Variants were then annotated using ANNOVAR (v2017-07-17) to include information from refGene, gnomAD (March 2017), 1000 Genomes (August 2015), ExAC, genomicSuperDups, COSMIC (v70), and dbSNP (v147) databases. CADD,<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> MPC<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> were used to annotate variant functional consequence.</p>
</sec>
<sec id="Sec21">
<title>Preprocessing and QC</title>
<p id="Par48">To reduce the noise introduced by our variant calling approach, we preprocessed our variants using a set of filters. Since our method is allelic depth-dependent, we took a conservative filtering approach to reduce the impact of false positives on model parameter estimation. We first filtered our variant call set for rare heterozygous coding variants (MAF ≤ 1 × 10<sup>−4</sup> across all populations represented in gnomAD and ExAC databases). To account for regions in the reference genome that are more challenging to resolve, we removed variant sites found in regions of nonunique mappability (score &lt;1; 300 bp), likely segmental duplication (score &gt;0.95), and known low complexity.<sup><xref ref-type="bibr" rid="CR77">77</xref></sup> We then excluded sites located in <italic>MUC</italic> and <italic>HLA</italic> genes and imposed a maximum variant read depth threshold of 500. To account for common technical artifacts, we used SAMtools PV4 <italic>p</italic>-values with a threshold of 1 × 10<sup>−3</sup> to exclude sites with evidence of baseQ bias, mapQ bias, and tail distance bias. To account for potential strand bias, we used an in-house script to flag sites that have either (1) 0 alternate allele read support on either the forward or reverse strand or (2) <italic>p</italic> &lt; 1 × 10<sup>−3</sup> and OR &lt; 0.33 or OR &gt; 3 when applying Fisher’s method to compare strand based reference or alternative allele counts. Finally, we excluded sites with frequency &gt;1% in the SPARK pilot, as well as sites belonging to outlier samples (with abnormally high de novo SNV counts, cutoff = 7) and complex variants (defined as sites with neighboring de novo SNVs within 10 bp).</p>
</sec>
<sec id="Sec22">
<title>IGV visualization of low allele fraction de novo SNVs</title>
<p id="Par49">To identify likely false positives among our low allele fraction (VAF &lt;0.3) de novo SNVs, we used Integrative Genomics Viewer (IGV v2.3.97) to visualize the local read pileup at each variant across all members of a given trio. We focused on the allele fraction range 0.0–0.3 since this range captures the majority of the technical artifacts that will negatively impact downstream parameter estimation. Sites were filtered out if (1) there were inconsistent mismatches in the reads supporting the mosaic allele, (2) the site overlapped or was adjacent to an indel, (3) the site had low MAPQ or was not primary alignment, (4) there was evidence of technical bias (strand, read position, tail distance), or (5) the site was mainly supported by soft-clipped reads.</p>
</sec>
<sec id="Sec23">
<title>Empirical bayes postzygotic mutation detection model</title>
<p id="Par50">To distinguish variant sites that show evidence of mosaicism from germline heterozygous sites, we modeled the number of reads supporting the variant allele (<italic>N</italic><sub><italic>alt</italic></sub>) as a function of the total site depth (<italic>N</italic>). In the typical case, <italic>N</italic><sub><italic>alt</italic></sub> follows a binomial model with parameters <italic>N</italic> = site depth and <italic>p-value</italic> <italic>=</italic> mean VAF. However, we observed notable overdispersion<sup><xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR79">79</xref></sup> in the distribution of variant allele fraction compared with the expectations under this binomial model. To account for this overdispersion, we instead modeled <italic>N</italic><sub><italic>alt</italic></sub> using a beta-binomial distribution. We estimated an overdispersion parameter <italic>θ</italic> for our model whereby for site depth values <italic>N</italic> in the range 1–500, we (1) bin variants by identifying all sites with depth <italic>N</italic>, (2) calculate a maximum-likelihood estimate <italic>θ</italic> value using <italic>N</italic> and all <italic>N</italic><sub><italic>alt</italic></sub> values for variants in a given bin, and (3) estimate a global <italic>θ</italic> value by taking the average of <italic>θ</italic> values across all bins, weighted by the number of variants in each bin.</p>
<p id="Par51">We used an expectation-maximization (EM) algorithm to jointly estimate the fraction of mosaics among apparent de novo mutations and the FDR of candidate mosaics. This initial mosaic fraction estimate gives a prior probability of mosaicism independent of sequencing depth or variant caller and allows us to calculate, for each variant in our input set, the posterior odds that a given site is mosaic rather than germline.</p>
<sec id="FPar1">
<title>Finalized union mosaic call set and validation selection</title>
<p id="Par52">The high confidence call sets from the two parallel mosaic determination approaches were combined, and all candidate mosaic variants were then inspected manually in IGV. Variants in regions with multiple mismatches or poor mapping quality were removed, and the remaining mosaics comprised the high confidence mosaic call set. For calls that were unique to one approach, the variant was annotated with which quality filter it initially failed. Variants that were flagged as low confidence germline by CUMC approach but mosaic by OHSU approach had posterior odds &gt;1 and were thus retained in the union call set.</p>
</sec>
<sec id="FPar2">
<title>CNV detection</title>
<p id="Par53">De novo and rare inherited CNVs were independently called by two centers—UW and SF. The final CNV list included all autosomal CNVs that were called by both SF and UW pipelines either with reciprocal overlap of at least 50% or when the CNV from one pipeline was completely within the CNV from the other pipeline. In both cases, the overlapping region was reported as the final region and annotated as described below. CNVs called only by one pipeline were considered as high confidence CNVs if they were called by at least two tools or if they were de novo CNVs confirmed by manual inspection of plots on exome data. High confidence CNVs were also included in the final list after discussion and manual inspection of plots on exome data. De novo CNVs were additionally inspected on BAF and LRR plots on genotyping data. CNVs that had at least 75% overlap with known segmental duplications (segDups track for hg19 from UCSC browser) were excluded. All CNVs were annotated with the list of RefSeq HG19 genes, OMIM genes, brain embryonically expressed genes,<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> brain critical genes,<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> ASD significant,<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> and ASD related genes<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup> that have their coding regions overlapping with the CNV. CNVs greater than or equal to 50 kbp in size were annotated with morbidity map<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> case and control frequencies using a 50% reciprocal overlap while CNVs &lt; 50 kbp were annotated with their frequency in the 1000 genomes project<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> using a 50% reciprocal overlap. We do note that it is possible some events may be missed with this annotation because of different platforms (e.g. exome, array, and genome), but the two analyses provide reasonable insight into the population prevalence of large and smaller CNVs in the general population. In addition, each found gene was annotated with pLI (ExAC release 0.3, <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/downloads">http://exac.broadinstitute.org/downloads</ext-link>), ASD,<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> RVIS,<sup><xref ref-type="bibr" rid="CR84">84</xref></sup> LGD,<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> and SFARI Gene scores (version q1, 2018, <ext-link ext-link-type="uri" xlink:href="https://gene.sfari.org/database/gene-scoring/">https://gene.sfari.org/database/gene-scoring/</ext-link>). dnCNVs that affect DUSP22 and olfactory genes were excluded due to high variability in copy number of those regions among individuals.<sup><xref ref-type="bibr" rid="CR86">86</xref></sup></p>
</sec>
</sec>
<sec id="Sec24">
<title>UW, detection using XHMM and CoNIFER</title>
<p id="Par54">CNVs from WES were called using CoNIFER and<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> XHMM.<sup><xref ref-type="bibr" rid="CR88">88</xref></sup> CoNIFER version v0.2.2 was used with the <italic>S</italic> value, –svd 7, set as a threshold as suggested by the scree plot. XHMM version statgen-xhmm-3c57d886bc96 was used with the following parameters –minTargetSize 10 –maxTargetSize 10000 –minMeanTargetRD 10 –maxMeanTargetRD 500 –minMeanSampleRD 25 –maxMeanSampleRD 200 –maxSdSampleRD 150 to filter samples and targets, and then to mean-center the targets; PVE_mean –PVE_mean_factor 0.7 was used to normalize mean-centered data using PCA information; –maxSdTargetRD 30 was used to filter and <italic>z</italic>-score centers (by sample) the PCA normalized data; and then to discover CNVs in all samples. Calls from CoNIFER and XHMM were merged in a VCF file using <ext-link ext-link-type="uri" xlink:href="https://github.com/zeeev/mergeSVcallers">https://github.com/zeeev/mergeSVcallers</ext-link> with the following parameters -t xhmm,conifer -r 0.5 -s 50000, then merged VCF was sorted by Picard version v2.5.0, and zipped and indexed with Tabix version v0.2.6. We re-genotyped each XHMM and CoNIFER CNV event by assessing the RPKM values from the CoNIFER workflow on an individual. Probands were considered to have a deletion if their average RPKM value was less than −1.5 s.d and have a duplication if their average RPKM value was greater than 1.5 s.d. For an event to be considered as variant in a parent, we required an average ZRPKM less than −1.3 or greater than 1.3 for deletions and duplications, respectively.</p>
</sec>
<sec id="Sec25">
<title>UW, CNV validation using SNP microarray</title>
<p id="Par55">We generated an independent CNV callset for validation purpose using SNP microarray genotyping data generated from Illumina InfiniumCoreExome-24_v1.1, where IDATs (<italic>n</italic> = 1,421) were processed using Illumina Genome Studio Software. CNV analysis was performed using the Illumina CNVpartition algorithm version v3.2.0. Log R Ratio data for all samples and probes was exported. PennCNV<sup><xref ref-type="bibr" rid="CR89">89</xref></sup> version v1.0.4 was used to detect CNVs with the following parameters -test –hmm -pfb all.pfb –gcmodelfile –confidence. We determined the maximum and minimum overlap of SNP microarray CNVs based on the presence of WES probes to make the array calls more similar to the exome calls and considered an event to have support by PennCNV or CNVpartition if there was at least 50% reciprocal overlap. We also generated per probe copy number estimates using CRLMM<sup><xref ref-type="bibr" rid="CR90">90</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup> version 1.38.0 as previously described<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and genotyped each candidate WES CNV. Deletions were considered variant if they had a <italic>p</italic>-value less than 0.05 and a mean percentile rank less than 30. Duplications were considered variant if they had a <italic>p</italic>-value less than 0.05 and a percentile rank of mean greater than 70. CNVs passing the RPKM genotyping were combined with the CNV data from CRLMM, PennCNV, and CNVPartition. We considered WES CNVs as valid if there was support for gain or loss from the PennCNV, CNVpartition, or CRLMM approaches described above. We assessed inheritance using both SNP and WES data and preferentially scored inherited events over de novo CNVs.</p>
</sec>
<sec id="Sec26">
<title>SF</title>
<p id="Par56">CNVs were called with two tools - xHMM v 1.0<sup><xref ref-type="bibr" rid="CR92">92</xref></sup> and CLAMMS v 1.1.<sup><xref ref-type="bibr" rid="CR93">93</xref></sup> xHMM<bold>:</bold> CNVs were called with default settings (except not filtering on the maximum target size), including filtering low complexity and GC extreme targets. CLAMMS: CNVs were called with INSERT_SIZE = 390 bp and training per-sample-models on sample specific reference panels due to the observed batch effect in the data; CLAMMS calls were filtered for all CNVs with Q_EXACT less than 0, or Q_SOME less than 100, or CNVs that were in samples with more than 70 predicted CNVs of the size at least 10 Kb and of quality score Q_SCORE at least 300. The inheritance status of the autosomal CNVs was determined by default xHMM protocol for de novo CNVs identification with plink 1.07<sup><xref ref-type="bibr" rid="CR94">94</xref></sup> and Plink/Seq 0.10 [<ext-link ext-link-type="uri" xlink:href="https://atgu.mgh.harvard.edu/plinkseq/">https://atgu.mgh.harvard.edu/plinkseq/</ext-link>]. Similar protocol was implemented in java for CLAMMS analysis. For each tool, two tiers of CNV calls—the most confident calls (tier 1) and less confident calls (tier 2)—were defined, based on de novo and transmission rates for different cuts on quality scores: SQ (phred-scaled quality of some CNV event in the interval) and NQ (phred-scaled quality of not being diploid, i.e., DEL or DUP event in the interval) in xHMM and Q_SOME (phred-scaled quality of any CNV being in this interval) in CLAMMS. xHMM tier1 included all autosomal CNVs with both SQ and NQ quality scores of at least 60, and tier2—all autosomal CNV calls with quality scores between 30 and 60. Samples with more than 10 de novo CNVs in xHMM tier1 of size at least 10 kb were excluded. CLAMMS tier1 included all predictions with quality score 999, except predictions for 25 probands that have CNVs of size greater than 500 kb with quality score 999 or predictions, which region was partially inherited and partially de novo; tier 2 included those excluded from tier 1 predictions as well as all CNVs with quality score Q_SOME at least 400 and less than 999. Predictions by both methods that had less than 3 exons or at least 75% overlap with known segmental duplications (segDups track for hg19 from UCSC browser) were removed from the list. The final list of CNV predictions included all CNVs from tier 1 predicted by either xHMM or CLAMMS and “intersection” of tier 2 sets from both tools, that is, CNVs that were confirmed by two tools with reciprocal or cumulative reciprocal overlap of at least 50%. In the latter case, CNV predicted by one tool is covered by a set of CNVs predicted by the other tool. If a CNV from xHMM or CLAMMS was confirmed by the other tool, the overlapping region was reported as the final region. CNVs were removed from the analysis if it had more than half of its length overlapping with the ACMG secondary findings v2 gene<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> (except <italic>PTEN, TSC1</italic>, and <italic>TSC2</italic>). If such gene covers less than 50% of CNV, the part of CNV without the gene was kept if it has at least 25% of its length not covered by segmental duplications. To identify higher confidence CNV predictions, xHMM and CLAMMS plots were manually investigated for each CNV in the final SF list. In addition, SF predictions were compared with PennCNV<sup><xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR95">95</xref>,<xref ref-type="bibr" rid="CR96">96</xref></sup> calls from array data, which have confidence score of at least 100. All reciprocal overlaps of at least 50% were treated as additional evidence for CNV support.</p>
</sec>
<sec id="Sec27">
<title>UW, chromosome aneuploidy assessment</title>
<p id="Par57">We also assessed evidence of chromosomal aneuploidy by calculating sequence read depth using SAMTools<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> version 1.4 on a per chromosome basis normalizing by the relative density of WES probes and comparing the normalized value for each chromosome to the normalized value on chromosome 1 (assumed to be diploid). For autosomes, we multiplied this number by two to get the estimate of chromosomal copy number. We did not multiply by two for the X or Y chromosomes. To further assess the chromosomal copy number, the heterozygosity was calculated for all SNPs and indels. For heterozygous sites, the absolute mean deviation from 0.5 was also calculated. We assessed both metrics to identify outliers. Aneuploidies were required to have support from both the read depth and SNP/indel metrics.</p>
</sec>
</sec>
<sec id="Sec28">
<title>Burden of de novo variants</title>
<p id="Par58">Baseline mutation rates for different classes of de novo variants in each GENCODE coding gene were calculated using a previously described mutation model.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> Briefly, the trinucleotide sequencec context was used to determine the probability of each base mutating to each other possible base. Then the mutation rate of each functional class of point mutations in a gene was calculated by adding up the mutation rate of each nucleotide in the longest transcript. The rate of frameshift indels was presumed to be 1.1 times the rate of nonsense point mutations. The expected number of variants in different gene sets were calculated by summing up the class-specific variant rate in each gene in the gene set multiplied by twice the number of patients (and if on chromosome X, further adjusted for female-to-male ratio<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>).</p>
<p id="Par59">The observed number of variants in each gene set and case group was then compared with the baseline expectation using a Poisson test. In all analyses, constrained genes were defined by a pLI score of ≥0.5. To compare with previously published ASD studies, we collected published de novo variants identified in 4773 simplex trios from three largest ASD studies to date.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup> To account for platform differences, the baseline mutation rate of each gene was scaled so that the exome-wide expected number of silent variants matches the observed count.</p>
</sec>
<sec id="Sec29">
<title>TADA analysis</title>
<p id="Par60">To perform TADA analysis of de novo variants, we assumed the fraction of disease genes is 5% as estimated by previous studies.<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR98">98</xref></sup> The prior relative risk for LGD variants and D-mis (defined by CADD &gt; = 25) were specified as Gamma (18,1) and Gamma (6,1). The prior mean relative risks were determined using the relationship between burden and relative risk as described previously.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> The baseline mutation rate of each gene was the same as used in burden analysis. The analysis was performed on de novo variants of 4773 published trios and after combing de novo variants identified from SPARK pilot trios.</p>
</sec>
<sec id="Sec30">
<title>Laminal layer and cell type enrichment</title>
<p id="Par61">To evaluate the expression specificity of laminal layer of human developing cortex, we analyzed RNA-seq data of neocortical samples of BrainSpan<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> following the method of Parikshak et al.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> The expression specificity was measured by a <italic>t</italic>-statistic comparing the expression level in each layer against all other layers. Two candidate ASD risk genes (<italic>PAX5, KDM1B</italic>) were not included in the analysis due to the low expression levels (RPKM &lt;1 for at least 20% available neocortical samples). To evaluate cell-type specificity, we used published data of mouse neuronal cell types inferred from analyzing single cell RNA-seq data of fetal and adult mouse brains generated by the Karolinska Institutet (KI),<sup><xref ref-type="bibr" rid="CR99">99</xref></sup> and human CNS cell types inferred from a single nucleus RNA-seq data.<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> The mouse orthologs of human genes were retrieved from MGI database.<sup><xref ref-type="bibr" rid="CR100">100</xref></sup> The cell-type specificity was measured by a specificity index which is the mean expression level in one cell type over the summation of mean expression level across all cell types.<sup><xref ref-type="bibr" rid="CR101">101</xref></sup> To analyze the overall trend of specificity of a gene set, the mean specificity measure of its genes was compared with 10,000 sets of randomly drawn genes matched for the transcript length and GC content and the enrichment is measured by the standard deviation from the mean specificity of random gene sets.<sup><xref ref-type="bibr" rid="CR101">101</xref></sup></p>
</sec>
<sec id="Sec31">
<title>Network and functional analysis</title>
<p id="Par62">The network depicted in Fig. <xref ref-type="fig" rid="Fig2">2a</xref> was constructed using the top decile of forecASD genes, SFARI Genes scoring 1 or 2, and SPARK newly implicated genes (6 in total). These genes were projected onto the STRING network<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> (v10) using the igraph R package (1708 genes). Edges within the STRING network were thresholded at 0.4, according to the authors’ recommendation. The largest connected subcomponent (1664 genes) was then extracted as the basis for further network analysis. Clustering was performed on the fully connected network using the fastgreedy community function available within the igraph package. Clusters with fewer than 30 genes were not considered for further analysis (none of these clusters contained the six genes highlighted here). Following the first round of clustering, clusters with &gt;150 genes were subject to an additional round of clustering, with the goal of separating broad functions of genes into more specific subcomponents. This process resulted in ten clusters. Each cluster was assessed for functional enrichment using the Gene Ontology<sup><xref ref-type="bibr" rid="CR103">103</xref></sup> as accessed through the clusterProfiler package within R. During the functional analysis the background gene universe was always set to the full set of genes represented among the ten clusters. Visualization of this network analysis was performed in Cytoscape.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> The top five most significant GO terms associated with each cluster are available in the Supplementary Data <xref ref-type="media" rid="MOESM11">9</xref>. Cluster labels in Fig. <xref ref-type="fig" rid="Fig2">2</xref> were chosen as the most representative among the top terms for each cluster. Figure <xref ref-type="fig" rid="Fig2">2b</xref> was constructed using the subset of the larger network (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>), corresponding to SPARK newly implicated genes and SFARI Gene genes scoring 1 or 2 (88 genes). These genes were projected onto the STRING network within Cytoscape using the STRINGapp. All nonzero-weighted edges were considered. The fully connected component was visualized, which resulted in two genes being dropped (<italic>DEAF1</italic> and <italic>RANBP17</italic>). Edges adjacent to newly implicated genes with a STRING interaction score of ≥0.4 are highlighted.</p>
<sec id="Sec32">
<title>ForecASD analysis</title>
<p id="Par63">We used a recently developed method, forecASD<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> that indexes support for a gene being related to ASD by integrating genetic, expression, and network evidence through machine learning. We examined the forecASD scores of candidate ASD risk genes from the TADA analysis and compared them to the remainder of the genome using a Wilcoxon rank-sum test. We similarly used the Wilcoxon test and employed two predictive features used by forecASD (BrainSpan_score and STRING_score) to assess whether the new genes showed similarity to known ASD risk genes in terms of brain expression patterns and network connectivity. Importantly, because forecASD uses previously published TADA scores among its predictive features, which are strongly correlated with updated TADA scores, we investigated whether the elevated forecASD scores in our candidate genes could be explained solely by the previous TADA scores. Specifically, we fit a logistic regression model with the candidate ASD risk genes labeled as ‘1’ and 500 size-matched background genes (not listed in the SFARI gene database) labeled as ‘0’ in the dependent variable (Y). Separate models were fit using either forecASD or TADA<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> scores as predictors, or both together in a full model. Both TADA and forecASD were significantly associated with the “new gene” indicator when considered in isolation (<italic>P</italic> &lt;0.001 for both, <italic>Z</italic>-test on logistic regression coefficients). However, when included together in a model of Y, forecASD remained significantly associated (<italic>p</italic>-value = 0.00012, <italic>Z</italic>-test on logistic regression coefficients) while TADA lost significance (<italic>p</italic>-value = 0.41, <italic>Z</italic>-test on logistic regression coefficients). The Akaike information criterion (AIC) indicated that the forecASD-only model was a more optimal fit compared with either the TADA-only or TADA + forecASD fit. This analysis suggests that the elevated forecASD scores observed in the ten new genes cannot be fully explained by the use of TADA as a predictor in forecASD.</p>
</sec>
</sec>
<sec id="Sec33">
<title>Reporting summary</title>
<p id="Par64">Further information on research design is available in the <xref ref-type="media" rid="MOESM2">Nature Research Reporting Summary</xref> linked to this article.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec34">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41525_2019_93_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41525_2019_93_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41525_2019_93_MOESM3_ESM.xlsx"><caption><p>Data Set 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41525_2019_93_MOESM4_ESM.xlsx"><caption><p>Data Set 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41525_2019_93_MOESM5_ESM.xlsx"><caption><p>Data Set 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41525_2019_93_MOESM6_ESM.xlsx"><caption><p>Data Set 4</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41525_2019_93_MOESM7_ESM.xlsx"><caption><p>Data Set 5</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41525_2019_93_MOESM8_ESM.xlsx"><caption><p>Data Set 6</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="41525_2019_93_MOESM9_ESM.xlsx"><caption><p>Data Set 7</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="41525_2019_93_MOESM10_ESM.xlsx"><caption><p>Data Set 8</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="41525_2019_93_MOESM11_ESM.xlsx"><caption><p>Data Set 9</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="41525_2019_93_MOESM12_ESM.xlsx"><caption><p>Data Set 10</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher’s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>These authors contributed equally: Pamela Feliciano, Xueya Zhou, Irina Astrovskaya, Tychele N. Turner</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p><bold>Supplementary information</bold> accompanies the paper on the <italic>npj Genomic Medicine</italic> website (10.1038/s41525-019-0093-8).</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We are extremely grateful to the thousands of individuals and families who are participating in this study. We are grateful to the many ASD advocacy and service organizations that have helped us inform the community about SPARK, including the Autism Society of America and its affiliates, Autism Speaks, Autism Science Foundation, Easter Seals, Arkansas Autism Resource and Outreach Center, Global and Regional Asperger’s Syndrome Partnership, Kentucky Autism Training Center, and Autistic Self Advocacy Network. We thank the members of SPARK’s Community Advisory Council for providing feedback and advice. We thank members of our Scientific and Community Advisory Board and SFARI scientists for advice on our protocol and participant outreach and retention strategies. We thank PreventionGenetics for managing and processing biospecimens, DNA Genotek for handling saliva kit logistics, and Baylor College of Medicine Human Genome Sequencing Center for exome sequencing. The SPARK initiative is funded by the Simons Foundation as part of SFARI. This research was supported, in part, by a grant from the National Institute of Mental Health (NIMH R01MH101221) and a grant from the Simons Foundation (SFARI #608045) to E.E.E., a grant from the National Institute of Mental Health to T.N.T. (1K99MH117165) and grants MH105527 and DC014489 from the National Institute of Health to L.B. and J.J.M. E.E.E. is an investigator of the Howard Hughes Medical Institute. B.J.O. is a Klingenstein-Simons Fellow (Esther A. &amp; Joseph Klingenstein Fund, Simons Foundation).</p>
</ack>
<notes notes-type="author-contribution">
<title>Author contributions</title>
<p>P.F., X.Z., I. Astrovskaya, T.N.T., J.J.M., B.J.O., N.V., Y.S. and W.K.C. designed and conceived the study. A.C., A.C.G., A.D.S., A.E., A.G., A.J., A.J.A., A.L.R., A.M., A.M.D., A.N., A.N.S., A.P., A.P.M., A.R.S., A. Swanson, B.A.H., B.E.R., B. Hauf, B.J.O., B.M.V., B.V., C.A., C.A.E., C.C., C.E.R., C. Harkins, C. Hayes, C.H.W., C.J.S., C. Lord, C.O., C.R.R., C.T., D.E.S., D.G.A., D.I., D. Lee Coury, D. Li, E.A.F., E. Berry-Kravis, E.C., E.J.F., E.L., E.L.W., E.M.B., E.O., E.T.M., G.M., G.S.D., H.E.K., H.H., H. Lam Schneider, H. Lechniak, H. Li, H. Zaydens, I. Arriaga, J.A., J.A.G., J.F.C., J.G., J.L., J.M., J.N., J.O., J.P., J.P., J.S., J.S.S., J.T., J.T.M., J. Wallace, K.A.S., K.C., K.E.H., K.G.P., K.L.P., K.O., K. Roeder, L.A., L.A.C., L. Beeson, L.D., L.D.P., L.G.S., L.M.H., L.M.P., L.P.G., L.S., L.V.S., L. Wasserburg, L. Casey White, L.Y.H., M.A., M.C., M. Heyman, M. Jones, M. Jordy, M.J.M., M.N.H., M.S., M.T., M.Y., N.B., N. Hanna, N. Harris, N. Lillie, N.R., N.T., O.Y.O., P.F., P.M., R.A. Bernier, R.D.A., R.D.C., R.J.L., R.P.G., R. Remington, R.T.S., S.B., S.C., S.E., S.F., S.G., S.H., S.J., S.J.B., S.J.L., S.L.F., S.L.H., S.M.K., S.P., S.Q., S. Sandhu, S.T., S.W., V.J.M., V.S., W.K.C., W.S.Y., and Z.W. recruited participants and collected clinical data and biospecimens. A. Balasubramanian, A. Beaudet, A.F., A.H., A.J. Griswold, A.K., A. Soucy, B.J.O., C.L Martin, C.N., D.H.G., E. Berry-Kravis, E. Bahl, E.E.E., E.R., H. Doddapaneni, H.Q., H.Zhang, H.Zhao, I. Astrovskaya, J.B.H., J.H., J.J.M., J.S.S., J.V., J. Wang, K. Rajbhandari, L. Brueggeman, L.G.S., L.P.G., L.Z., M.G., M.R.G., M.Y.D., N.V., P.F., R.A. Barnard, R.D., R.D.A., S.L., S.M., S. Santangelo, S. Skinner, S.X., T.K., T.N.T., T.P., T.S., T.T., T.W., T.Y., V.G., V.K., W.K.C., X.L., X.Z., Y.D., Y.S., and Z.M. helped with data interpretation. A.A., A. Bashar, A.E.L., A. Salomatov, A.S.C., B. Han, C.M.S., C.R., I. Astrovskaya, I.F., J.A., J.B.H., K.L., M.D.M., M.E.B., M.K., N.C., N. Lawson, N.V., R.M., R. Rana, S.G., S. Shah, S.X., W.C., and W.J. built and supported the SPARKforAutism.org website, software, databases and systems, and managed SPARK data. A.D.K., A.H., A.J. Gruber, A. Sabo, B.J.O., C.E., D.M., E. Brooks, G.J.F., I. Astrovskaya, J.J.M., L. Brueggeman, L.G.S. M.P., M.R.G., N.V., P.F., R.A. Barnard, R.A.G., T.N.T., T.W., W.K.C., X.Z., and Y.S. performed analyses, processed biospecimens and sequenced DNA samples. P.F. and W.K.C. supervised the work. P.F., X.Z., I. Astrovskaya, T.N.T., J.J.M., B.J.O., N.V., W.K.C., and Y.S. wrote this paper.</p>
</notes>
<notes notes-type="data-availability">
<title>Code availability</title>
<p>Methods for SNV, Indels, CNV analysis are available at <ext-link ext-link-type="uri" xlink:href="https://genomicpipelines.sparkforautism.org/">https://genomicpipelines.sparkforautism.org/.</ext-link></p>
</notes>
<notes notes-type="data-availability">
<title>Data availability</title>
<p>The genomic and phenotypic data for the 1379 individuals analyzed in this study is available by request from SFARIBase (<ext-link ext-link-type="uri" xlink:href="https://www.sfari.org/resource/sfari-base/">https://www.sfari.org/resource/sfari-base/</ext-link>) with accession ID: SFARI_SPARK_WES_p.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par65">M.S. has received research funding from Roche, Novartis, Pfizer, Aucta, Navitor, Rugen, Ibsen, Neuren, LAM Therapeutics, Quadrant Biosciences and has served on the Scientific Advisory Board of Sage Therapeutics, Roche and Takeda. D.H.G. receives research funding from Takeda Pharmaceuticals, and consulting fees or equity participation for scientific advisory board work from Ovid Therapeutics, Axial Bio-therapeutics, Acurastem, and Falcon Computing. E.E.E. is on the scientific advisory board (SAB) of DNAnexus, Inc. All other authors declare no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schendel</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of psychiatric and neurologic comorbidity with mortality among persons with autism spectrum disorder in a danish population</article-title>
<source/>JAMA Pedia.
          <year>2016</year>
<volume>170</volume>
<fpage>243</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1001/jamapediatrics.2015.3935</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandin</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The heritability of autism spectrum disorder</article-title>
<source/>JAMA
          <year>2017</year>
<volume>318</volume>
<fpage>1182</fpage>
<lpage>1184</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2017.12141</pub-id>
<pub-id pub-id-type="pmid">28973605</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The contribution of de novo coding mutations to autism spectrum disorder</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>216</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature13908</pub-id>
<pub-id pub-id-type="pmid">25363768</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>RK</surname>
<given-names>CY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder</article-title>
<source/>Nat. Neurosci.
          <year>2017</year>
<volume>20</volume>
<fpage>602</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4524</pub-id>
<pub-id pub-id-type="pmid">28263302</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tammimies</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder</article-title>
<source/>JAMA
          <year>2015</year>
<volume>314</volume>
<fpage>895</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2015.10078</pub-id>
<pub-id pub-id-type="pmid">26325558</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>SPARK Consortium</collab>
</person-group>
<article-title>SPARK: A US Cohort of 50,000 families to accelerate autism research</article-title>
<source/>Neuron
          <year>2018</year>
<volume>97</volume>
<fpage>488</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2018.01.015</pub-id>
<pub-id pub-id-type="pmid">29420931</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rubeis</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>209</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1038/nature13772</pub-id>
<pub-id pub-id-type="pmid">25363760</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci</article-title>
<source/>Neuron
          <year>2015</year>
<volume>87</volume>
<fpage>1215</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.09.016</pub-id>
<pub-id pub-id-type="pmid">26402605</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samocha</surname>
<given-names>KE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A framework for the interpretation of de novo mutation in human disease</article-title>
<source/>Nat. Genet.
          <year>2014</year>
<volume>46</volume>
<fpage>944</fpage>
<lpage>950</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3050</pub-id>
<pub-id pub-id-type="pmid">25086666</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kircher</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>
<source/>Nat. Genet
          <year>2014</year>
<volume>46</volume>
<fpage>310</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2892</pub-id>
<pub-id pub-id-type="pmid">24487276</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<mixed-citation publication-type="other">Samocha, K. E. et al. Regional missense constraint improves variant deleteriousness prediction. 10.1101/148353 (2017).</mixed-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lek</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>
<source/>Nature
          <year>2016</year>
<volume>536</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
<pub-id pub-id-type="pmid">27535533</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A higher mutational burden in females supports a “female protective model” in neurodevelopmental disorders</article-title>
<source/>Am. J. Hum. Genet
          <year>2014</year>
<volume>94</volume>
<fpage>415</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2014.02.001</pub-id>
<pub-id pub-id-type="pmid">24581740</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excess of rare, inherited truncating mutations in autism</article-title>
<source/>Nat. Genet.
          <year>2015</year>
<volume>47</volume>
<fpage>582</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3303</pub-id>
<pub-id pub-id-type="pmid">25961944</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosmicki</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples</article-title>
<source/>Nat. Genet
          <year>2017</year>
<volume>49</volume>
<fpage>504</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3789</pub-id>
<pub-id pub-id-type="pmid">28191890</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>CF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data</article-title>
<source/>Lancet
          <year>2015</year>
<volume>385</volume>
<fpage>1305</fpage>
<lpage>1314</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61705-0</pub-id>
<pub-id pub-id-type="pmid">25529582</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Consortium, G. T.</collab>
<etal></etal>
</person-group>
<article-title>Genetic effects on gene expression across human tissues</article-title>
<source/>Nature
          <year>2017</year>
<volume>550</volume>
<fpage>204</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1038/nature24277</pub-id>
<pub-id pub-id-type="pmid">29022597</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A copy number variation morbidity map of developmental delay</article-title>
<source/>Nat. Genet
          <year>2011</year>
<volume>43</volume>
<fpage>838</fpage>
<lpage>846</lpage>
<pub-id pub-id-type="doi">10.1038/ng.909</pub-id>
<pub-id pub-id-type="pmid">21841781</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uddin</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder</article-title>
<source/>Nat. Genet
          <year>2014</year>
<volume>46</volume>
<fpage>742</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2980</pub-id>
<pub-id pub-id-type="pmid">24859339</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between microdeletion and microduplication at 16p11.2 and autism</article-title>
<source/>N. Engl. J. Med.
          <year>2008</year>
<volume>358</volume>
<fpage>667</fpage>
<lpage>675</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa075974</pub-id>
<pub-id pub-id-type="pmid">18184952</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freed</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pevsner</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The contribution of mosaic variants to autism spectrum disorder</article-title>
<source/>PLoS Genet
          <year>2016</year>
<volume>12</volume>
<fpage>e1006245</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1006245</pub-id>
<pub-id pub-id-type="pmid">27632392</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>ET</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder</article-title>
<source/>Nat. Neurosci.
          <year>2017</year>
<volume>20</volume>
<fpage>1217</fpage>
<lpage>1224</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4598</pub-id>
<pub-id pub-id-type="pmid">28714951</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krupp</surname>
<given-names>DR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exonic mosaic mutations contribute risk for autism spectrum disorder</article-title>
<source/>Am. J. Hum. Genet
          <year>2017</year>
<volume>101</volume>
<fpage>369</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.07.016</pub-id>
<pub-id pub-id-type="pmid">28867142</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>HJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathway</article-title>
<source/>Genes Dev.
          <year>2006</year>
<volume>20</volume>
<fpage>1933</fpage>
<lpage>1945</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1411206</pub-id>
<pub-id pub-id-type="pmid">16815997</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takata</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrative analyses of de novo mutations provide deeper biological insights into autism spectrum disorder</article-title>
<source/>Cell Rep.
          <year>2018</year>
<volume>22</volume>
<fpage>734</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.074</pub-id>
<pub-id pub-id-type="pmid">29346770</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes</article-title>
<source/>PLoS Genet.
          <year>2013</year>
<volume>9</volume>
<fpage>e1003671</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1003671</pub-id>
<pub-id pub-id-type="pmid">23966865</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiatt</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deleterious Variation in BRSK2 Associates with a Neurodevelopmental Disorder</article-title>
<source/>Am. J. Hum. Genet
          <year>2019</year>
<volume>104</volume>
<fpage>701</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2019.02.002</pub-id>
<pub-id pub-id-type="pmid">30879638</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrent de novo mutations implicate novel genes underlying simplex autism risk</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<fpage>5595</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms6595</pub-id>
<pub-id pub-id-type="pmid">25418537</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>MS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Haploinsufficiency of NR4A2 is associated with a neurodevelopmental phenotype with prominent language impairment</article-title>
<source/>Am. J. Med Genet. A
          <year>2017</year>
<volume>173</volume>
<fpage>2231</fpage>
<lpage>2234</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.38288</pub-id>
<pub-id pub-id-type="pmid">28544326</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NR4A2 haploinsufficiency is associated with intellectual disability and autism spectrum disorder</article-title>
<source/>Clin. Genet
          <year>2018</year>
<volume>94</volume>
<fpage>264</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1111/cge.13383</pub-id>
<pub-id pub-id-type="pmid">29770430</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Epi</surname>
<given-names>KC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in epileptic encephalopathies</article-title>
<source/>Nature
          <year>2013</year>
<volume>501</volume>
<fpage>217</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1038/nature12439</pub-id>
<pub-id pub-id-type="pmid">23934111</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inherited and multiple de novo mutations in autism risk genes suggests a multifactorial model</article-title>
<source/>Mol. Autism
          <year>2018</year>
<volume>9</volume>
<fpage>64</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-018-0247-z</pub-id>
<pub-id pub-id-type="pmid">30564305</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional impact of global rare copy number variation in autism spectrum disorders</article-title>
<source/>Nature
          <year>2010</year>
<volume>466</volume>
<fpage>368</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="doi">10.1038/nature09146</pub-id>
<pub-id pub-id-type="pmid">20531469</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maussion</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Implication of LRRC4C and DPP6 in neurodevelopmental disorders</article-title>
<source/>Am. J. Med Genet. A
          <year>2017</year>
<volume>173</volume>
<fpage>395</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.38021</pub-id>
<pub-id pub-id-type="pmid">27759917</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darnell</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism</article-title>
<source/>Cell
          <year>2011</year>
<volume>146</volume>
<fpage>247</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.06.013</pub-id>
<pub-id pub-id-type="pmid">21784246</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayes</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of the proteome, diseases and evolution of the human postsynaptic density</article-title>
<source/>Nat. Neurosci.
          <year>2011</year>
<volume>14</volume>
<fpage>19</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2719</pub-id>
<pub-id pub-id-type="pmid">21170055</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TBR1 directly represses Fezf2 to control the laminar origin and development of the corticospinal tract</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2011</year>
<volume>108</volume>
<fpage>3041</fpage>
<lpage>3046</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1016723108</pub-id>
<pub-id pub-id-type="pmid">21285371</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tourtellotte</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Milbrandt</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3</article-title>
<source/>Nat. Genet.
          <year>1998</year>
<volume>20</volume>
<fpage>87</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1038/1757</pub-id>
<pub-id pub-id-type="pmid">9731539</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory</article-title>
<source/>Mol. Cell Neurosci.
          <year>2007</year>
<volume>35</volume>
<fpage>76</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2007.02.004</pub-id>
<pub-id pub-id-type="pmid">17350282</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<mixed-citation publication-type="other">Brueggeman, L., Koomar, T. &amp; Michaelson, J. Forecasting autism gene discovery with machine learning and genome-scale data. 10.1101/370601 (2018).</mixed-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gacek-Matthews</surname>
<given-names>Agnieszka</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>Harald</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>Takahiko</given-names>
</name>
<name>
<surname>Wittstein</surname>
<given-names>Kathrin</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>Clemens</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>Zachary A.</given-names>
</name>
<name>
<surname>Strauss</surname>
<given-names>Joseph</given-names>
</name>
</person-group>
<article-title>KdmB, a Jumonji Histone H3 Demethylase, Regulates Genome-Wide H3K4 Trimethylation and Is Required for Normal Induction of Secondary Metabolism in Aspergillus nidulans</article-title>
<source/>PLOS Genetics
          <year>2016</year>
<volume>12</volume>
<issue>8</issue>
<fpage>e1006222</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1006222</pub-id>
<pub-id pub-id-type="pmid">27548260</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lilley</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Sanes</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>SAD kinases sculpt axonal arbors of sensory neurons through long- and short-term responses to neurotrophin signals</article-title>
<source/>Neuron
          <year>2013</year>
<volume>79</volume>
<fpage>39</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.05.017</pub-id>
<pub-id pub-id-type="pmid">23790753</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gryaznova</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gubar</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Burdyniuk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kropyvko</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rynditch</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>WIP/ITSN1 complex is involved in cellular vesicle trafficking and formation of filopodia-like protrusions</article-title>
<source/>Gene
          <year>2018</year>
<volume>674</volume>
<fpage>49</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2018.06.078</pub-id>
<pub-id pub-id-type="pmid">29958948</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willsey</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism</article-title>
<source/>Cell
          <year>2013</year>
<volume>155</volume>
<fpage>997</fpage>
<lpage>1007</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.10.020</pub-id>
<pub-id pub-id-type="pmid">24267886</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parikshak</surname>
<given-names>NN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism</article-title>
<source/>Cell
          <year>2013</year>
<volume>155</volume>
<fpage>1008</fpage>
<lpage>1021</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.10.031</pub-id>
<pub-id pub-id-type="pmid">24267887</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodato</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene co-regulation by Fezf2 selects neurotransmitter identity and connectivity of corticospinal neurons</article-title>
<source/>Nat. Neurosci.
          <year>2014</year>
<volume>17</volume>
<fpage>1046</fpage>
<lpage>1054</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3757</pub-id>
<pub-id pub-id-type="pmid">24997765</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Control of species-dependent cortico-motoneuronal connections underlying manual dexterity</article-title>
<source/>Science
          <year>2017</year>
<volume>357</volume>
<fpage>400</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1126/science.aan3721</pub-id>
<pub-id pub-id-type="pmid">28751609</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transcriptional landscape of the prenatal human brain</article-title>
<source/>Nature
          <year>2014</year>
<volume>508</volume>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1038/nature13185</pub-id>
<pub-id pub-id-type="pmid">24695229</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skene</surname>
<given-names>NG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic identification of brain cell types underlying schizophrenia</article-title>
<source/>Nat. Genet
          <year>2018</year>
<volume>50</volume>
<fpage>825</fpage>
<lpage>833</lpage>
<pub-id pub-id-type="doi">10.1038/s41588-018-0129-5</pub-id>
<pub-id pub-id-type="pmid">29785013</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habib</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Massively parallel single-nucleus RNA-seq with DroNc-seq</article-title>
<source/>Nat. Methods
          <year>2017</year>
<volume>14</volume>
<fpage>955</fpage>
<lpage>958</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.4407</pub-id>
<pub-id pub-id-type="pmid">28846088</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>GN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Spatiotemporal 16p11.2 protein network implicates cortical late mid-fetal brain development and KCTD13-Cul3-RhoA pathway in psychiatric diseases</article-title>
<source/>Neuron
          <year>2015</year>
<volume>85</volume>
<fpage>742</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.01.010</pub-id>
<pub-id pub-id-type="pmid">25695269</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richards</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>
<source/>Genet. Med.
          <year>2015</year>
<volume>17</volume>
<fpage>405</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>
<pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuen</surname>
<given-names>RK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-genome sequencing of quartet families with autism spectrum disorder</article-title>
<source/>Nat. Med
          <year>2015</year>
<volume>21</volume>
<fpage>185</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3792</pub-id>
<pub-id pub-id-type="pmid">25621899</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppa</surname>
<given-names>VM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare Inherited and De Novo CNVs Reveal Complex Contributions to ASD Risk in Multiplex Families</article-title>
<source/>Am. J. Hum. Genet
          <year>2016</year>
<volume>99</volume>
<fpage>540</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.06.036</pub-id>
<pub-id pub-id-type="pmid">27569545</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Crump</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Sanes</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Mammalian SAD kinases are required for neuronal polarization</article-title>
<source/>Science
          <year>2005</year>
<volume>307</volume>
<fpage>929</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="doi">10.1126/science.1107403</pub-id>
<pub-id pub-id-type="pmid">15705853</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakob</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intersectin 1 is a component of the Reelin pathway to regulate neuronal migration and synaptic plasticity in the hippocampus</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2017</year>
<volume>114</volume>
<fpage>5533</fpage>
<lpage>5538</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1704447114</pub-id>
<pub-id pub-id-type="pmid">28484035</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<mixed-citation publication-type="other">Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. (2019). <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/484113v3">https://www.biorxiv.org/content/10.1101/484113v3</ext-link>.</mixed-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bodfish</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Symons</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Varieties of repetitive behavior in autism: comparisons to mental retardation</article-title>
<source/>J. Autism Dev. Disord.
          <year>2000</year>
<volume>30</volume>
<fpage>237</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1023/A:1005596502855</pub-id>
<pub-id pub-id-type="pmid">11055459</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<mixed-citation publication-type="other">Rutter, M., Bailey, A. J. &amp; Lord, C. Social communication questionnaire (SCQ). (2003).</mixed-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>BN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychometric properties of the revised Developmental Coordination Disorder Questionnaire</article-title>
<source/>Phys. Occup. Ther. Pedia.
          <year>2009</year>
<volume>29</volume>
<fpage>182</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1080/01942630902784761</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism</article-title>
<source/>J. Autism Dev. Disord.
          <year>2000</year>
<volume>30</volume>
<fpage>205</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1023/A:1005592401947</pub-id>
<pub-id pub-id-type="pmid">11055457</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Le Couteur</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders</article-title>
<source/>J. Autism Dev. Disord.
          <year>1994</year>
<volume>24</volume>
<fpage>659</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="doi">10.1007/BF02172145</pub-id>
<pub-id pub-id-type="pmid">7814313</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Durbin</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Fast and accurate short read alignment with Burrows–Wheeler transform</article-title>
<source/>Bioinformatics
          <year>2009</year>
<volume>25</volume>
<fpage>1754</fpage>
<lpage>1760</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id>
<pub-id pub-id-type="pmid">19451168</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenna</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
<source/>Genome Res
          <year>2010</year>
<volume>20</volume>
<fpage>1297</fpage>
<lpage>1303</lpage>
<pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
<pub-id pub-id-type="pmid">20644199</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The sequence Alignment/Map format and SAMtools</article-title>
<source/>Bioinformatics
          <year>2009</year>
<volume>25</volume>
<fpage>2078</fpage>
<lpage>2079</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id>
<pub-id pub-id-type="pmid">19505943</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manichaikul</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Robust relationship inference in genome-wide association studies</article-title>
<source/>Bioinformatics
          <year>2010</year>
<volume>26</volume>
<fpage>2867</fpage>
<lpage>2873</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btq559</pub-id>
<pub-id pub-id-type="pmid">20926424</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<mixed-citation publication-type="other">Garrison, E., Gabor, M. Haplotype based variant detection from short-read sequencing. <italic>arXiv</italic><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1207.3907">https://arxiv.org/abs/1207.3907</ext-link> (2012).</mixed-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danecek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>BCFtools/csq: haplotype-aware variant consequences</article-title>
<source/>Bioinformatics
          <year>2017</year>
<volume>33</volume>
<fpage>2037</fpage>
<lpage>2039</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btx100</pub-id>
<pub-id pub-id-type="pmid">28205675</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DePristo</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title>
<source/>Nat. Genet.
          <year>2011</year>
<volume>43</volume>
<fpage>491</fpage>
<lpage>498</lpage>
<pub-id pub-id-type="doi">10.1038/ng.806</pub-id>
<pub-id pub-id-type="pmid">21478889</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rimmer</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications</article-title>
<source/>Nat. Genet
          <year>2014</year>
<volume>46</volume>
<fpage>912</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3036</pub-id>
<pub-id pub-id-type="pmid">25017105</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>A gradient-boosting approach for filtering de novo mutations in parent-offspring trios</article-title>
<source/>Bioinformatics
          <year>2014</year>
<volume>30</volume>
<fpage>1830</fpage>
<lpage>1836</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btu141</pub-id>
<pub-id pub-id-type="pmid">24618463</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hakonarson</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>
<source/>Nucleic Acids Res.
          <year>2010</year>
<volume>38</volume>
<fpage>e164</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id>
<pub-id pub-id-type="pmid">20601685</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrow</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GENCODE: the reference human genome annotation for The ENCODE Project</article-title>
<source/>Genome Res.
          <year>2012</year>
<volume>22</volume>
<fpage>1760</fpage>
<lpage>1774</lpage>
<pub-id pub-id-type="doi">10.1101/gr.135350.111</pub-id>
<pub-id pub-id-type="pmid">22955987</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalia</surname>
<given-names>SS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics</article-title>
<source/>Genet. Med.
          <year>2017</year>
<volume>19</volume>
<fpage>249</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2016.190</pub-id>
<pub-id pub-id-type="pmid">27854360</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cingolani</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3</article-title>
<source/>Fly
          <year>2012</year>
<volume>6</volume>
<fpage>80</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.4161/fly.19695</pub-id>
<pub-id pub-id-type="pmid">22728672</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Improving SNP discovery by base alignment quality</article-title>
<source/>Bioinformatics
          <year>2011</year>
<volume>27</volume>
<fpage>1157</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btr076</pub-id>
<pub-id pub-id-type="pmid">21320865</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Freudenberg</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Mappability and read length</article-title>
<source/>Front. Genet.
          <year>2014</year>
<volume>5</volume>
<fpage>381</fpage>
<pub-id pub-id-type="pmid">25426137</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heinrich</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The allele distribution in next-generation sequencing data sets is accurately described as the result of a stochastic branching process</article-title>
<source/>Nucleic Acids Res.
          <year>2012</year>
<volume>40</volume>
<fpage>2426</fpage>
<lpage>2431</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkr1073</pub-id>
<pub-id pub-id-type="pmid">22127862</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramu</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of genetic diversity in the sorghum reference set using EST-SSR markers</article-title>
<source/>Theor. Appl. Genet.
          <year>2013</year>
<volume>126</volume>
<fpage>2051</fpage>
<lpage>2064</lpage>
<pub-id pub-id-type="doi">10.1007/s00122-013-2117-6</pub-id>
<pub-id pub-id-type="pmid">23708149</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stessman</surname>
<given-names>HA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases</article-title>
<source/>Nat. Genet
          <year>2017</year>
<volume>49</volume>
<fpage>515</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3792</pub-id>
<pub-id pub-id-type="pmid">28191889</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Refining analyses of copy number variation identifies specific genes associated with developmental delay</article-title>
<source/>Nat. Genet.
          <year>2014</year>
<volume>46</volume>
<fpage>1063</fpage>
<lpage>1071</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3092</pub-id>
<pub-id pub-id-type="pmid">25217958</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudmant</surname>
<given-names>PH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An integrated map of structural variation in 2,504 human genomes</article-title>
<source/>Nature
          <year>2015</year>
<volume>526</volume>
<fpage>75</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1038/nature15394</pub-id>
<pub-id pub-id-type="pmid">26432246</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>1454</fpage>
<lpage>1462</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4353</pub-id>
<pub-id pub-id-type="pmid">27479844</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<mixed-citation publication-type="other">Petrovski, S. et al. GenicIntolerance to functional variation and the interpretation of personal genomes. <italic>PLoS</italic><italic>Genetics</italic><bold>9</bold> (2013).</mixed-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low load for disruptive mutations in autism genes and their biased transmission</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2015</year>
<volume>112</volume>
<fpage>E5600</fpage>
<lpage>E5607</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1516376112</pub-id>
<pub-id pub-id-type="pmid">26401017</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extensive copy-number variation of the human olfactory receptor gene family</article-title>
<source/>Am. J. Hum. Genet
          <year>2008</year>
<volume>83</volume>
<fpage>228</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2008.07.005</pub-id>
<pub-id pub-id-type="pmid">18674749</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krumm</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Copy number variation detection and genotyping from exome sequence data</article-title>
<source/>Genome Res
          <year>2012</year>
<volume>22</volume>
<fpage>1525</fpage>
<lpage>1532</lpage>
<pub-id pub-id-type="doi">10.1101/gr.138115.112</pub-id>
<pub-id pub-id-type="pmid">22585873</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth</article-title>
<source/>Am. J. Hum. Genet.
          <year>2012</year>
<volume>91</volume>
<fpage>597</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.08.005</pub-id>
<pub-id pub-id-type="pmid">23040492</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data</article-title>
<source/>Genome Res
          <year>2007</year>
<volume>17</volume>
<fpage>1665</fpage>
<lpage>1674</lpage>
<pub-id pub-id-type="doi">10.1101/gr.6861907</pub-id>
<pub-id pub-id-type="pmid">17921354</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Hetrick</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Tavare</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>R/Bioconductor software for Illumina’s Infinium whole-genome genotyping BeadChips</article-title>
<source/>Bioinformatics
          <year>2009</year>
<volume>25</volume>
<fpage>2621</fpage>
<lpage>2623</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btp470</pub-id>
<pub-id pub-id-type="pmid">19661241</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharpf</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ruczinski</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Using the R Package crlmm for genotyping and copy number estimation</article-title>
<source/>J. Stat. Softw.
          <year>2011</year>
<volume>40</volume>
<fpage>1</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.18637/jss.v040.i12</pub-id>
<pub-id pub-id-type="pmid">22523482</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Using XHMM software to detect copy number variation in whole-exome sequencing data</article-title>
<source/>Curr. Protoc. Hum. Genet
          <year>2014</year>
<volume>81</volume>
<fpage>7 23 21</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">24763994</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Packer</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CLAMMS: a scalable algorithm for calling common and rare copy number variants from exome sequencing data</article-title>
<source/>Bioinformatics
          <year>2016</year>
<volume>32</volume>
<fpage>133</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">26382196</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>
<source/>Am. J. Hum. Genet.
          <year>2007</year>
<volume>81</volume>
<fpage>559</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="doi">10.1086/519795</pub-id>
<pub-id pub-id-type="pmid">17701901</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diskin</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms</article-title>
<source/>Nucleic Acids Res.
          <year>2008</year>
<volume>36</volume>
<fpage>e126</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkn556</pub-id>
<pub-id pub-id-type="pmid">18784189</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modeling genetic inheritance of copy number variations</article-title>
<source/>Nucleic Acids Res.
          <year>2008</year>
<volume>36</volume>
<fpage>e138</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkn641</pub-id>
<pub-id pub-id-type="pmid">18832372</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Deciphering Developmental Disorders, S.</collab>
</person-group>
<article-title>Large-scale discovery of novel genetic causes of developmental disorders</article-title>
<source/>Nature
          <year>2015</year>
<volume>519</volume>
<fpage>223</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1038/nature14135</pub-id>
<pub-id pub-id-type="pmid">25533962</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>HT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders</article-title>
<source/>Genome Med.
          <year>2017</year>
<volume>9</volume>
<fpage>114</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-017-0497-y</pub-id>
<pub-id pub-id-type="pmid">29262854</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeisel</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular architecture of the mouse nervous system</article-title>
<source/>Cell
          <year>2018</year>
<volume>174</volume>
<fpage>999</fpage>
<lpage>1014 e1022</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.06.021</pub-id>
<pub-id pub-id-type="pmid">30096314</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eppig</surname>
<given-names>JT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>D726</fpage>
<lpage>D736</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku967</pub-id>
<pub-id pub-id-type="pmid">25348401</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skene</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment</article-title>
<source/>Front. Neurosci.
          <year>2016</year>
<volume>10</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00016</pub-id>
<pub-id pub-id-type="pmid">26858593</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STRING v10: protein-protein interaction networks, integrated over the tree of life</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>D447</fpage>
<lpage>D452</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id>
<pub-id pub-id-type="pmid">25352553</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashburner</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene ontology: tool for the unification of biology. the gene ontology consortium</article-title>
<source/>Nat. Genet
          <year>2000</year>
<volume>25</volume>
<fpage>25</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1038/75556</pub-id>
<pub-id pub-id-type="pmid">10802651</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>
<source/>Genome Res.
          <year>2003</year>
<volume>13</volume>
<fpage>2498</fpage>
<lpage>2504</lpage>
<pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
<pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A systematic variant annotation approach for ranking genes associated with autism spectrum disorders</article-title>
<source/>Mol. Autism
          <year>2016</year>
<volume>7</volume>
<fpage>44</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-016-0103-y</pub-id>
<pub-id pub-id-type="pmid">27790361</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>